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CHAPTER 1 
G E N E R A L I N T R O D U C T I O N 
Asthma, chronic obstructive bronchit is and emphysema are diseases of the 
respiratory system with air f low obstruction as a main character is t ic . The 
air f low obstruction is a consequence of di f fuse narrowing of the airways which 
may be t rans i to ry , prolonged or even permanent in nature. 
Asthma is a c l i n i ca l state of increased reac t i v i t y of the airways to various 
st imul i and air f low obstruction that changes in severi ty either spontaneously 
or through therapy (American Thoracic Society 1962). Many asthmatics have an 
a l lerg ic const i tut ion and are hypersensitive to inhaled allergens. 
IgE-specific antibodies for these antigens can be demonstrated on the surface 
of mast ce l ls and basophilic polymorphonuclear leukocytes (Wasserman 1983). 
Activat ion of these ce l ls results into release of a var iety of b io log ica l ly 
active mediators. The mediators can induce smooth muscle contract ion, edema of 
the bronchial wall and inflammation, resul t ing in narrowing of the airways. An 
a l lerg ic const i tut ion is not a prerequisite for bronchial hyperreact iv i ty in 
asthma. A number of asthmatic patients apparently has no a l lerg ic const i tut ion 
and air f low obstruction can be induced by non-allergic st imul i also, such as 
exercise, cold air and other i r r i t a n t s t imu l i . 
In chronic obstructive bronchi t is , air f low obstruction is more persistent . 
The patients suffer from excessive mucus secretion, manifested by chronic or 
recurrent productive cough (American Thoracic Society 1962). Chronic 
obstructive bronchit is is associated with hyperplasia and hypertrophy of 
submucosal glands, increased thickness of the bronchial wall caused by 
inflammation and formation of f ibrous t issue, loss of c i l i a ted epithelium and 
mucus plugging of the airways. Bronchoconstriction may contribute to ai r f low 
obstruction in chronic obstructive bronchi t is . A considerable number of 
patients have an increased reac t i v i t y to i r r i t a n t st imul i (Ramsdell et a l . 
1982). 
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Airf low obstruction in emphysema is hardly revers ib le. I t is caused by a 
diminished e l a s t i c i t y of the lung due to destruction of the alveolar walls 
where the elast ic f ibres reside (American Thoracic Society 1962). As a 
consequence a narrowing and sometimes collaps of the airways occur during 
expirat ion. Addi t ional ly , an increased airway reac t i v i t y to i r r i t a n t s t imul i 
may be encountered in patients with emphysema (Slui ter et a l . 1961). 
Obstruction of air f low can easily be demonstrated by forced expiratory 
volume reg is t ra t ion (Fig. 1). The patient is instructed to take the deepest 
possible inspirat ion and then to exhale maximally and as fast as possible into 
a spirometer which records the volume exhaled over time. Usually, the volume 
that is exhaled during the f i r s t second ("FEVi") is taken as index of 
a i r f low obstruct ion. FEVi c a n a^so be expressed as percentage of the v i ta l 
capacity ("VC") which is the maximal volume that can be exhaled from the lungs 
after a maximal insp i ra t ion . 
volume ( I ) 
5 time (sec) 
Fig. 1: Forced expiratory volume registrations in a normal subject (continuous 
line) and a patient with obstructive lung disease (dashed line). 
FEVi = f°rced expiratory volume in 1 sec. 
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In clinical practice, it is not always possible to differentiate clearly 
between asthma, chronic obstructive bronchitis and emphysema. Patients may 
show various disease symptoms and transitions of the clinical picture in the 
course of life. Therefore, these clinical entities are regarded as different 
manifestations of the same syndrome designated collectively chronic 
jionspecific J_un9 .disease ("CNSLD") with "CARA" (chronische ¿specifieke 
Respiratoire _aandoeningen) as the Dutch equivalent (Orie et al. 1961). 
BRONCHIAL HYPERREACTIVITY 
Bronchial hyperreactivity is an increased susceptibility to nonspecific 
stimuli resulting in airway smooth muscle contraction and a diminished 
airflow. A number of causes has been proposed including: (i) an increased 
accessibility of the sensory nerve endings in the epithelium due to a damaged 
airway mucosa (Laitinen et al. 1985a), (ii) a pre-existing reduced airway 
caliber (Ariëns 1980) and (iii) mechanical changes in the airway smooth muscle 
itself (Antonissen et al. 1979). 
Bronchial hyperreactivity may also originate from an autonomic imbalance 
between the contracting muscarinic cholinergic and α-adrenergic systems, and 
the relaxing ß-adrenergic and nonadrenergic noncholinergic systems regulating 
the airway smooth muscle tone. This imbalance can either result from an 
overactivity of the contracting or from an inadequate functioning of the 
relaxing mechanisms. 
In the present thesis, the question is addressed whether muscarinic 
cholinergic and ß-adrenergic receptors are altered in airway smooth muscle of 
patients with asthma, chronic obstructive bronchitis and emphysema. In the 
following paragraphs, the autonomic regulation of human airways will be 
described, and pharmacological and biochemical aspects of ß-adrenergic and 
muscarinic receptors will be discussed. 
INNERVATION OF THE HUMAN AIRWAYS 
The respiratory tract is supplied with a complex network of afferent and 
efferent nerve fibres involved in the regulation of the diverse tissue types. 
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The afferent input stems predominantly from pulmonary sensory nerve endings 
("sensory receptors") and travels via the vagus nerve to the central nervous 
system. Several types of sensory receptors have been described including 
myelinated rapidly adapting nerve endings designated "irritant receptors" and 
nonmyelinated C-fibre endings. These sensory systems, present in airway 
epithelium, respond to mechanical and chemical irritation (Hahn 1986). The 
complicated network of epithelial innervation with numerous collateral 
branches may give rise to axonic reflexes. 
The efferent output is classically described as occurring through 
parasympathetic and sympathetic nerves. Parasynpathetic (cholinergic) 
preganglionic fibres innervating the respiratory tract are contained in the 
vagus nerve and relay with short postganglionic fibres in the vicinity of or 
in the airway wall. Sympathetic preganglionic fibres emerge from the spinal 
medulla, traverse to the sympathetic trunk and synapse with postganglionic 
fibres. In the vicinity of the airways, the parasympathetic and sympathetic 
fibres are arranged into two basic plexi, a periarterial and a peribronchial 
plexus and the latter subdivided into an extrachondrial and a subchondrial 
part. Along the peribronchial plexus, parasympathetic ganglia are scattered to 
the level of the smaller bronchi and found mainly extrachondrially (Partanen 
et al. 1982). In the airway walls, parasympathetic fibres innervate smooth 
muscle cells and submucosal glands but are absent in blood vessels and airway 
epithelium (Partanen et al. 1982). 
Sympathetic fibres are located around submucosal glands and blood vessels. The 
existence of adrenergic innervation of smooth muscle cells is still a matter 
of controversy. While some investigators (Daniel et al. 1980; Partanen et al. 
1982) observed a few adrenergic fibres innervating airway smooth muscle, 
others (Richardson and Béland 1976; Doidge and Satchel 1 1982) were not able to 
trace any. 
There is strong evidence for the existence of a third type of neural control 
of human airways which is neither adrenergic nor cholinergic. Electric field 
stimulation of nerves produces contraction followed by relaxation of the 
airway smooth muscle. The contraction can be abolished by muscarinic 
cholinergic antagonists leaving the relaxation which is not affected by 
ß-adrenergic antagonists (Richardson and Béland 1976; Davis et al. 1982; 
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Taylor et al. 1984). The relaxation is nerve mediated as tetrodotoxin, a 
blocker of axonal conduction, specifically abolishes the relaxation. The 
neurotransmitter of this so-called nonadrenergic noncholinergic system is 
unknown but there is evidence for vasoactive intestinal polypeptide ("VIP") 
fulfilling this role (Barnes 1986a). Besides that, it is possible that VIP 
plays a role in the regulation of mucus and water secretion, and cholinergic 
transmission through parasympathetic ganglia (Dey et al. 1981; Laitinen et 
al. 1985b; Barnes 1986a; Carstairs and Barnes 1986). 
Other peptides, for example peptide histidine methionine ("PHM") have been 
implicated as neurotransmitter of the nonadrenergic relaxation in human 
airways as well (Palmer et al. 1985). 
CHOLINERGIC MECHANISMS 
Electrical stimulation of peripheral ends of the cut vagus nerve as well as 
cholinomimetic drugs induce airway smooth muscle contraction and accelerate 
mucus secretion from submucosal glands (Richardson and Beland 1976; Goldie et 
al. 1982; Shelhamer et al. 1980). These responses are blocked by low 
concentrations of atropine indicating that they are mediated by muscarinic 
receptors. 
In asthmatics, and to a lesser extent in patients with chronic obstructive 
bronchitis, cholinomimetic drugs provoke bronchoconstriction, in dosages which 
in general have no effect in normal, healthy subjects. The response can be 
prevented by muscarinic antagonists. There is evidence that muscarinic 
antagonists also give protection against noncholinergic irritant stimuli 
(Gross and Skorodin 1984). 
These findings prompt the suggestion that bronchial hyperreactivity is a 
consequence of increased vagal activity or enhanced cholinergic sensitivity of 
airway smooth muscle. Vagal activity may be increased by stimulation of 
afferent sensory receptors or by facilitation of parasympathetic 
neurotransmission by inflammatory mediators (Hahn 1986). 
Bronchial hyperreactivity could also be explained by an increase in muscarinic 
receptor sensitivity; either by an increase in receptor number or by a more 
effective coupling with the contractile apparatus. An inherent muscarinic 
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receptor defect, however, seems unl ikely as the increased responsiveness is 
not rest r ic ted to muscarinic cholinergic agonists and muscarinic antagonists 
do not f u l l y protect against a l l bronchoconstricting st imul i (Gross and 
Skorodin 1984). 
There is evidence that airway epithelium is involved in the regulation of 
smooth muscle tone. Removal of the e p i t h e l i a l layer increases contract i le 
responses of isolated airway smooth muscle preparations of several species, 
including man (Fl avahan et a l . 1985; Barnes et a l . 1985; Raeburn et a l . 
1986). I t has been suggested that e p i t h e l i a l c e l l s secrete an i n h i b i t o r y 
relaxant factor (Flavahan et a l . 1985). Since bronchial epithelium of patients 
with asthma and chronic obstructive bronchit is is often seriously damaged or 
even absent, a decreased production of the epithel ішп-derived relaxant factor 
would no longer warrant protection against constr ict ing s t i m u l i . 
ADRENERGIC MECHANISMS 
Adrenergic regulation of human airways is brought about by c i r c u l a t i n g 
adrenaline secreted by the adrenal medulla, and by noradrenaline released from 
postganglionic sympathetic f i b r e s . 
Adrenaline and noradrenaline exert the i r action by act ivat ion of adrenergic 
receptors ("adrenoceptors"). Adrenoceptors can be divided into two classes 
designated α and β. The c l a s s i f i c a t i o n is based upon the effect and order of 
potency of catecholamines in various organs and t issues: α-adrenoceptors 
generally mediate contraction of smooth muscle (order of potency adrenaline > 
noradrenaline » isoprenaline) whereas ß-adrenoceptors mediate relaxation 
(Ahlquist 1948). ß-Adrenoceptors can be divided into two subclasses: 
ßl-adrenoceptors (order of potency isoprenaline > noradrenaline > 
adrenaline) and ß2-adrenoceptors (order of potency isoprenaline > adrenaline 
» noradrenaline) (Lands et a l . 1967). 
Arië'ns and Simonis (1983) have proposed a functional "raison d 'e t re" for the 
ß-adrenoceptor subtypes. In the i r view, the ßi-adrenoceptor is pr imari ly a 
receptor for the neurotransmitter noradrenaline, and the ß2-adrenoceptor is 
the receptor for the hormone adrenaline. The theory predicts absence of 
ßl-adrenoceptors when there is no direct adrenergic innervation and seems to 
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be f u l f i l l e d in human airway smooth muscle. Pharmacological studies have 
provided strong evidence for a homogeneous ß2-adrenoceptor population in 
human airway smooth muscle (Zaagsma et a l . 1983; Goldie et a l . 1984) and 
histological studies indicate that airway smooth muscle is almost devoid of 
adrenergic innervation. This means that airway smooth muscle relaxation in man 
is mediated in the f i r s t place by c i rcu la t ing adrenaline and not by neuronally 
released noradrenaline. 
With respect to α-adrenoceptors, noradrenaline does not have any ef fect or 
gives only weak contraction of bronchial s t r ips from healthy subjects, even 
after ß-adrenoceptor blockade (Mathé et a l . 1971; Simonsson et a l . 1972; 
Kneussl and Richardson 1978; Goldie et a l . 1982). Thus α-adrenoceptor-mediated 
bronchial contraction is not to be considered of any importance in airways of 
healthy subjects. In str ips of peripheral lung, noradrenaline causes 
contraction (Black et a l . 1981; Goldie et a l . 1982). I t has been suggested 
that t h i s is due to stimulation of α-adrenoceptors in vascular smooth muscle 
(Goldie et a l . 1982) or to stimulation of α-adrenoceptors in parasympathetic 
ganglia and nerves inducing release of acetylcholine (Black 1986). 
In addition to a d i r e c t action on smooth muscle c e l l s , a- and ß-adrenergic 
agonists may exert the i r influence ind i rec t ly by stimulating and inh ib i t ing 
release of mediators from mast ce l ls (Orange et a l . 1971; Kaliner et a l . 1972) 
or by modulating neurotransmission through cholinergic and nonadrenergic 
nonchoiinerqic nerves via presynaptic adrenoceptors in parasympathetic ganglia 
and nerve endings (Vermeire and Vanhoutte 1979; Kamikawa and Shimo 1986). 
α-Adrenoceptor function in bronchial hyperreactivity 
There is consensus in the l i t e r a t u r e that α-adrenoceptors are of minor 
importance in the airway regulation of normal subjects. Inhalation of 
α-adrenergic agonists does not produce bronchoconstriction. 
In asthmatic pat ients, however, a-adrenerqic agonists induce air f low 
obstruct ion, especial ly after ß-adrenoceptor blockade (Simonsson et a l . 1972; 
Black et a l . 1982). I t may be caused by an increased α-adrenoceptor 
s e n s i t i v i t y in asthmatic airway smooth muscle but i t might also r e f l e c t the 
nonspecific hyperreact iv i ty in asthma. 
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Functional studies with airway smooth muscle of patients with airway disease 
have generated c o n f l i c t i n g data. Goldie et a l . (1985) found normal 
α-adrenoceptor responses in asthmatic airway smooth muscle while Adolphson et 
a l . (1971), Kneussl and Richardson (1978) observed enhanced a-adrenoceptor 
mediated contraction of airway smooth muscle of patients with respiratory 
disease. Using radioligand binding techniques, Raaymakers et a l . (1984) 
observed increased oq-adrenoceptor numbers in lung tissue of patients with 
chronic obstructive lung disease. The location of these increased receptor 
numbers however remains to be established. 
As mentioned before, besides a d irect action on airway smooth muscle i t s e l f , 
α-adrenergic agonists may exert their ef fect through vascular smooth muscle 
contraction and through release of other bronchoconstricting substances. Black 
(1986) recently showed that the bronchoconstricting effects of α-adrenergic 
agonists are inhibi ted by the muscarinic antagonist ipratropium bromide, 
suggesting that the response is mediated through parasympathetic nerves. 
ß-Adrenoceptor function In bronchial hyperreactivity 
A ß-adrenoceptor dysfunction in asthma has been postulated by Szentivanyi 
(1968). Szentivanyi based his hypothesis on experiments with Bordetella 
pertussis-vaccinated mice and ra ts . The infected animals showed a reduced 
sens i t i v i t y to catecholamines accompanied with responses comparable to those 
found in patients with asthma. The hyperreact ivi ty fol lowing vaccination was 
also observed after ß-adrenoceptor blockade. 
Ttie ß-adrenergic theory of Szentivanyi has triggered a lo t of research 
aiming at exploration of the role of adrenergic mechanisms in bronchial 
hyperreact iv i ty. Because in vivo studies in asthmatics are d i f f i c u l t to 
interpret and because asthmatic airway tissue for in v i t ro studies can be 
obtained only occasionally, the ß-adrenergic theory of Szentivanyi was 
i n i t i a l l y tested in animal models of asthma. Par t icu lar ly in guinea piqs 
supporting evidence was found. Douglas et a l . (1977) observed in guinea pigs 
an inverse relat ionship between histamine reac t i v i t y in vivo and isoprenaline 
sens i t i v i t y of airway smooth muscle in v i t r o . Others found a decreased 
pulmonary ß-adrenoceptor number in experimentally induced asthma in guinea 
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pigs (Barnes et a l . 1980; Mita et a l . 1982; Taki et a l . 1986). Kaukel and 
Rieckenberg (1980) as well as Schreurs and Nijkamp (1982) examined decreased 
ß-adrenoceptor relaxation responses in sensitized guinea pigs. 
Other ß-adrenergic abnormalities such as impaired secretion of adrenaline 
from the adrenal medulla (Ind et a l . 1985) and presence of auto-antibodies for 
the ß2-adrenoceptor (Venter et a l . 1980) have been suggested. 
Other experimental fac ts , however, are not in favour of an impaired 
ß-adrenoceptor function in bronchial hyperreact iv i ty . Asthmatics respond 
ef fec t ive ly to ß-adrenergic agonists and ß-adrenoceptor blockade in healthy 
subjects does not produce hyperreactivi ty (Boushey et a l . 1980). Therefore, i t 
is argued that ß-adrenoceptor dysfunction by i t s e l f is insu f f i c ien t to cause 
bronchial hyperreact iv i ty (Boushey et a l . 1980; Barnes 1986b). 
Nevertheless, some evidence for an impaired ß-adrenoceptor function in 
airway smooth muscle has been provided. Bronchial preparations of asthmatic 
patients display a diminished sens i t i v i t y to isoprenaline in relaxation 
experiments (Paterson et a l . 1982; Cerrina et a l . 1986). 
The controversies on ß-adrenoceptor anomalies in bronchial hyperreact iv i ty 
w i l l thus for some time be the subject of research e f f o r t s . 
β-ADRENOCEPTORS AND MUSCARINIC RECEPTORS 
ß-Adrenoceptors 
Stimulation of ß-adrenoceptors by agonists e l i c i t s an array of physiological 
responses in various t issues, most of them mediated through act ivat ion of 
adenylate cyclase. 
I t is now well established that agonist-induced stimulation of adenylate 
cyclase is brought about by consecutive coupling of the agonist-receptor 
complex with a guanine nucleotide binding prote in , designated either Gs or 
Ns and the cata ly t ic moiety of adenylate cyclase (St i les et a l . 1984). The 
subscript "s" in Ns and Gs stands for st imulatory. 
In the prevail ing model, depicted in Figure 2, the agonist-receptor complex 
(H.R) binds to the Gs prote in , bearing guanosine diphosphate (GDP). 
Formation of the ternary complex H.R.GStGgP is followed by exchange of GDP 
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for GTP leading to a destabi l izat ion. The ternary complex dissociates, 
rendering a GTP bearing Gs (GS ÍGTP) which interacts with the cata ly t ic 
moiety of adenylate cyclase (C) to form the enzymatically active GS#GTP.C. 
The l i fe t ime of th is active complex is l imited because of the GTP-ase ac t i v i t y 
of Gs, regenerating GS.GDP» a n inactive state of Gs. 
The model sa t i s fac to r i l y explains the shallow inh ib i t ion curves encountered 
when radiolabelled antagonists are displaced by agonists and the steepening of 
those curves when the inh ib i t ion is carried out in the presence of GTP. The 
shallow inh ib i t ion curves extending over a large concentration range of the 
agonists have been explained by postulating the existence of two agonist 
binding s i tes ; one with high and one with low a f f i n i t y for agonists. The high 
a f f i n i t y agonist s i te is thought to be the ternary complex H.R.GS#GDP in the 
scheme of Figure 2 whereas the low a f f i n i t y s i te represents the binary complex 
H.R . 
p-adrenoceptor Gs st imulat ion adenylate cyclase 
stimulation st imulat ion 
Fig . 2: Stimulation of adenylate cyclase by p-adrenoceptor agonist binding via 
a stimulatory guanine nucleotide binding protein Gg. 
In the presence of GTP, a l l the Gs w i l l associate with GTP counteracting 
formation of the ternary complex. Under these circumstances the agonist binds 
exclusively to the binary complex, re f lec t ing in an inh ib i t ion curve with a 
normal slope at high agonist concentrations. 
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The activity of adenylate cyclase, along with that of phosphodiesterase 
which catalyzes the hydrolysis of cAMP into inactive 5'-AMP, determines the 
cellular content of cAMP. cAMP activates specific cAMP-dependent protein 
kinases which in turn trigger a sequence of biochemical mechanisms leading to 
for instance relaxation of airway smooth muscle. 
Muscarinic Receptors 
The search for muscarinic receptor subtypes has a longlasting history (Barlow 
et al. 1972; Beid et al. 1975). The discovery of the non-classical muscarinic 
antagonist pirenzepine has been a major instrument for exploring muscarinic 
receptor subtypes. In radioligand binding studies pirenzepine exhibits up to 
50 fold higher affinity for muscarinic receptors in certain brain regions 
(Kj ~ 20 nM) than for those in heart and smooth muscle (Kj ~ 1000 nM) 
(Hammer et al. 1980). The unique receptor binding properties of pirenzepine 
have been affirmed in functional experiments (see El-Fakahany et al. 1986a for 
references). The binding data are compatible with the existence of at least 
two types of receptors for pirenzepine; the Ml receptor having high affinity 
and the M2 receptor having low affinity. The Ml receptors are found 
predominantly in the central nervous system and autonomic ganglia whilst those 
denoted as M2 receptors are located mainly in peripheral effector organs. 
Evidence is accumulating that the M2 receptors are not homogeneous either and 
a subdivision has already been proposed. For example, the compounds 
4-diphenylacetoxy N-methylpiperidine methiodide (4 DAMP, Barlow et al. 1976) 
and hexahydrosiladifenidol (Mutschler and Lambrecht 1984) display about 20 to 
30 times higher affinity for muscarinic receptors in the ileun than for atrium 
muscarinic receptors. A new muscarinic antagonist AF-DX 116 discriminates M2 
muscarinic receptors in heart (Kd ~ 115 nM) and glandular tissue (Kd ~ 3000 
nM) (Hammer et al. 1986). It may be expected that such compounds are the 
forerunners of agents with even better selectivity. 
The details of the biochemical responses upon muscarinic receptor activation 
have not been elucidated yet. Agonist competition curves are shallow extending 
over a wide concentration range and can be interpreted by assuming the 
existence of at least two subpopulations of agonist binding sites (Birdsall et 
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a l . 1978). At present, i t is not clear whether the complex binding behaviour 
is due to interconversion of d i f ferent states of the receptor, the existence 
of d i s t inc t receptor subtypes or a combination of the two. 
The properties of the d i f ferent agonist sites are now studied with respect to 
the biochemical and electrophysiological responses such as inh ib i t ion of 
adenylate cyclase, increase in phosphatidyl inosi to l (PI) turnover, st imulation 
of guanylate cyclase and regulation of transmembranal ion transport. 
Inh ib i t ion of adenylate cyclase may occur by a similar mechanism as 
considered for the act ivat ion of adenylate cyclase, with involvement of a 
GTP-binding protein designated GÌ or N, (the subscript " i " in Gi and 
Ni stands for inhib i tory) (Haga et a l . 1985; Flor io and Sternweis 1985; 
Helmreich and Pfeuffer 1985). 
Muscarinic receptor st imulation causes increased phosphoinositide turnover, 
resul t ing in the production of two second messengers inosi to l triphosphate 
(IP3) and diacylglycerol (DAG) from a common plasmamembrane substrate 
phosphatidyl inosi to l 4,5-diphosphate (PI А.б-Рг) (see Abdel-Latif 1986 for a 
review). In what way muscarinic receptor act ivat ion is translated into 
polyphosphoinositide (PPI) phosphodiesterase ("phospholipase C") a c t i v i t y is 
not known yet. There is increasing evidence that another GTP binding protein 
( t e n t a t i v e l y designated Gp) is involved (Cockcroft and Gomperts 1985; Smith 
et a l . 1986). IP3 diffuses from the plasma membrane to the endopl asmatic 
reticulum where i t releases Ca^ "1". The r ise in Ca^ "1" activates calmodulin 
which can activate myosin l i g h t chain kinase in smooth muscle. This enzyme 
then phosphorylates myosin leading to contract ion. 
The other second messenger diacylglycerol activates protein kinase С, a 
calcium and phospholipid sensitive protein kinase. Protein kinase С activates 
myosin d i r e c t l y (Abdel-Latif 1986; Barnes and Cuss 1986). From DAG arachidonic 
acid can be l iberated through the action of lipases for the synthesis of 
lipoxygenase and cycloxygenase products (e.g. leukotrienes, prostaglandins and 
thromboxanes). 
Other responses to muscarinic receptor act ivat ion are transmembranal ion 
transport and stimulation of guanylate cyclase (McKinney and Richelson 1984). 
In what way these responses are coupled to muscarinic receptors is unknown. 
Recently, evidence has been found that muscarinic receptors are coupled to ion 
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channels via GTP binding proteins (Pfaffinger et al. 1985; Breitwieser and 
Szabo 1985). 
Whether these biochemical and electrophysiological responses are 
specifically linked to one or the other agonist binding site is currently 
investigated (McKinney and Riche!son 1986; Akiyama et al. 1986; Harden et al. 
1986a, b). Comparison of agonist occupancy curves and biochemical response 
curves suggests that the high and low affinity agonist binding sites represent 
coupling states of agonist sites with particular biochemical responses: the 
high affinity site for inhibition of adenylate cyclase and the low affinity 
site for stimulation of PI turnover and guanylate cyclase. 
The question whether Ml and M2 receptors are coupled to a particular 
biochemical response has been addressed but convincing answers have not been 
given yet (McKinney et al. 1985; Gil and Wolfe 1985; Harden et al. 1986a). 
Another feature arguing for muscarinic receptor heterogeneity is the 
observation that the ability of guanosine triphosphate to convert high 
affinity agonist binding sites into low affinity sites is not the same in all 
tissues (Berrie et al. 1979; Ehlert et al. 1980). 
The picture is further complicated by recent findings that quaternary 
muscarinic antagonists like N-methylatropine, N-methylscopolamine, N-methyl 
quinuclidinyl benzilate and ipratropium discriminate subpopulations of 
muscarinic binding sites. (Ensing 1984; El-Fakahany et al. 1986b, Brown and 
Goldstein 1986). It remains to be established whether these subpopulations 
represent subtypes of muscarinic receptors or binding sites sequestered 
differently and therefore not equally accessible for the positively charged 
ligands. 
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O U T L I N E O F T H E T H E S I S 
The research described in the present thesis concerns the question whether the 
muscarinic and p-adrenergic receptors in airway smooth muscle of patients with 
asthma, chronic obstructive bronchit is and emphysema are altered. 
Muscarinic and ß-adrenergic receptors were investigated in tracheal 
musculature and bronchial t issue by receptor binding studies and functional 
experiments. The receptors were characterized with respect to antagonist and 
agonist binding propert ies. Their coupling with the contract i le and relaxant 
response was investigated in contraction and relaxation experiments. 
The characterization of the muscarinic and ß-adrenergic receptor population in 
tracheal smooth muscle of subjects free of airway disease, i s described in 
chapter 2 and 3. Muscarinic receptors were measured also in bronchial tissue 
which contain besides smooth muscle ce l l s other ce l lu la r components. In order 
to elucidate the or ig in of the muscarinic receptors in the tissue homogenates, 
the local izat ion of the receptors in human bronchi was studied (chapter 4) . In 
general, bronchial t issue was received only in very l imited amounts, 
insuf f ic ient to measure both receptors separately. Therefore, a "double 
receptor assay" was developed for simultaneous measurements in the same 
membrane preparation (chapter 5 ) . In chapter 6 and 7 the character ist ics of 
muscarinic and ß-adrenergic receptors in airway t issue of patients with 
asthma, chronic obstructive bronchit is and emphysema are described. Chapter 7 
also deals with the functional interaction between the receptor systems in the 
regulation of airway smooth muscle tone. 
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CHARACTERIZATION OF TIC MUSCARINIC RECEPTOR 
I N HUMAN TRACHEAL SMOOTH MUSCLE 
Chris J. van Koppen, Jaap F. Rodrigues de Miranda, Arie J. Beid, 
Marcel W. Hermanussen, Jan-Willem J. Lammers^ and Cees A.M. van Ginneken 
Departments of Pharmacology and Pulmonary Diseases^, University of Nijmegen 
SUMMARY 
Muscarinic receptors in human tracheal smooth muscle were characterized by 
radioligand binding and functional studies. Specific [ 3 H ] - ( - ) - Q N B binding to 
tracheal smooth muscle membranes was revers ib le, stereoselective and of high 
a f f i n i t y (Kd = 47 ± 4 pmol/1; Rj = 920 ± 120 fmol/g t issue) . 
Inh ib i t ion of specif ic [3H]-(-)-QNB binding by the M-l select ive antagonist 
pirenzepine was found to occur at re la t ive high concentrations c lassi fy ing the 
muscarinic receptor population as belonging to the M-2 subclass. 
Inh ib i t ion of specif ic [3H]-(-)-QNB binding by muscarinic agonists revealed 
the presence of high and low a f f i n i t y s i tes in nearly equal proportions. 
S'-Guanylylimidodiphosphate converted high a f f i n i t y sites into low a f f i n i t y 
s i tes although i t s ef fect was minimal. 
Log dose-contraction curves of methacholine had H i l l coef f ic ients of 1.10 ± 
0.04 with pDj-values of 6.75 ± 0.02. 
Inh ib i t ion of specif ic [ 3 H ] - ( - ) - Q N B binding by methacholine, however, was 
best described by a two binding site model with pK-j-values considerably 
lower. The difference between these potencies points to the presence of 
substantial receptor reserve. 
INTRODUCTION 
Human airway smooth muscle tone is regulated by exci tatory and inh ib i to ry 
autonomic neuronal and humoral mechanisms. Electr ic f i e l d stimulation of 
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d is ta l ends of cut vagus nerves as well as cholinomimetic drugs cause hunan 
airway smooth muscle to contract (Richardson and Beland 1976; Goldie et a l . 
1982). Although adrenergic innervation of the human bronchial musculature is 
questionable (Partanen et a l . 1982; Richardson and Beland 1976), ß-adrenergic 
agonists are potent relaxants of human airways. This suggests that c i rcu la t ing 
adrenaline rather than neuronally released noradrenaline is responsible for 
relaxation of human airway smooth muscle. 
Strong evidence has further been presented to support the existence of a th i rd 
type of airway con t ro l , the nonadrenergic inh ib i to ry system. Electr ic f i e l d 
stimulation of airway smooth muscle with in t r ins ic tone causes contraction 
followed by re laxat ion. In the presence of atropine contraction is abolished 
leaving relaxat ion. This relaxation is not due to adrenergic stimulation 
because i t is not inhibited by ß-adrenergic antagonists (Richardson and Beland 
1976; Taylor et a l . 1984). I t has been suggested that the nonadrenergic 
inh ib i to ry system is the principal neuronal mechanism for bronchodilatation. 
Beside these systems other non-neuronal excitatory and inhib i tory mechanisms 
determining bronchomotor tone exist (Taylor et a l . 1984). 
A defect in the ß-adrenergic regulatory system of the bronchomotor tone has 
been proposed as the major cause of bronchial hyperreact iv i ty in asthma 
(Szentivanyi 1968). Because in asthmatics as well as in normal subjects airway 
smooth muscle tone is considered to be maintained by parasympathetic ac t i v i t y 
(Severinghaus and Stupfel 1955); Widdicombe 1966), a defect could equally well 
be situated in the parasympathetic part of the regulat ion. An increased 
sens i t i v i t y of muscarinic receptors also would cause increased muscle tone. 
Present day knowledge of muscarinic receptors in human airway smooth muscle, 
however, is l imited and mainly stems from in v i t r o contraction and c l i n i ca l 
studies (Boushey et a l . 1980). Using radioligand binding techniques muscarinic 
receptors have been ident i f ied in bovine and canine tracheal smooth muscle 
(Van Koppen et a l . 1984; Murías et a l . 1982). However, histochemical studies 
have demonstrated considerable va r i ab i l i t y of innervation between species and 
extrapolation from one part icular animal species to man is of l imi ted value 
(Richardson 1979; Daniel et a l . 1980). 
The aim of the present investigation was the characterization of the 
muscarinic receptor population in human airway smooth muscle by radioligand 
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binding and functional techniques. Although the study of bronchial smooth 
muscle would be most relevant to obstructive airway disease, i t i s , however, 
exceedingly d i f f i c u l t to obtain homogeneous smooth muscle preparations from 
bronchi and smaller airways in s u f f i c i e n t amounts. Therefore, the tracheal 
smooth muscle was studied as the nearest good model for human airway smooth 
muscle. 
MATERIALS AND METHODS 
Materials 
Quinucl idinyl-benzi late, (R)-[benzil ic-4,4' -3H(N)] (sp. act. 123 χ ЮЮ 
Bq/mmol) ([3H]-(-)-QNB) was purchased from NEN Europe, Doorn, The 
Netherlands. (R)-Quinucl id inyl-benzi late Γ(-)-0ΝΒ] was a g i f t from Dr. G. 
Lambrecht, Johann Wolfgang Goethe-Universität, Frankfurt am Main, FRG. 
Pirenzepine and ipratropium bromide were g i f t s from Boehringer Ingelheim, 
FRG. Dexetimide and levetimide were g i f t s from Janssen Pharmaceutica, Beerse, 
Belgium. 
(±)Acetyl-ß-methylcholine (methachol ine) , phenylmethylsulfonylfluoride and 
S'-guanylyl imidodiphosphate were from Sigma Chemical Company, St. Louis, MO, 
USA. Methyl furtrethon i urn was synthesized in our laboratory according to known 
procedures. Al l other reagents were of analyt ical grade. 
Membrane preparation 
Human tracheae were received after a postmortem delay of 2 h (η = 2 ) , 3-6 h (η 
= 5 ) , 7-16 h (η = 2) and 17-24 h (η = 5 ) . The mean postmortem delay was 13 ± 8 
h (mean + SE). The time span between death and body r e f r i g e r a t i o n was 1-3 h. 
The mean age of the subjects was 60 ± 22 years, ranging from 11-81 years. 
Materials used was exclusively from subjects free of any h istory of 
respiratory disease who also had not received cholinergic therapy. After 
removal of the tracheal mucosa the smooth muscle layer was c l e a r l y v i s i b l e and 
freed from adhering connective t issue as good as possible. The smooth muscle 
was minced with a pair of scissors and homogenized by grinding with double 
i t s weight of carborumdum (120 mesh) in a mortar at CPC. The resul t ing pulp 
was suspended in modified Krebs-Ringer buffer pH 7.0 (composition in mmol/1 : 
NaCl 141, KCl 5, MgS04 1.3, Na2HP04 10, and СаСІг 1.3). 
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Carborundum was removed by centr i fugat ion (500 g force at maximum radius, 5 
min at ¿PC). The pel let was ground a second time and processed as before. The 
combined supernatants were centrifuged once more at 500 g^,^ for 5 min at 
¿PC to remove residual carborundum. Tiie resultant supernatant was centrifuged 
at 100,000 gmax for 1 h (40C) and the pel let stored at -2(PC unt i l use. 
Receptor assay 
Prior to use the membrane pel lets were suspended by Potter homogenization in 
Krebs-Ringer buffer pH 7.0 using a Braun homogenizer (15 strokes at 1,000 
rpm). The method used for the assay of par t i c le bound rad ioact iv i ty was the 
rapid centr i fugat ion of membrane fragments. Polypropylene microcentrifuge 
tubes (1.5 ml) received 70 μΐ [3H]-(-)-QNB in Krebs-Ringer buf fer , 70 μΐ 
Krebs-Ringer buffer with or without competing ligand and 700 μΐ t issue 
homogenate corresponding f i n a l l y with 15 mg/ml t issue. For equi l ibr iun binding 
experiments concentrations of [ 3 H ] - ( - ) - Q N B varied from 4 t o t 1,250 pmol/1, 
and for i n h i b i t i o n experiments a fixed concentration between 160-250 pmol/l 
was used. The tubes were incubated at ЗТ^С for 90 min while rotat ing (2 rpm) 
and then centrifuged at 18,000 χ g m a x for 15 min in a Heraeus Christ 
Hâmofuge. 
The free concentration of radioligand was measured by mixing 0.5 ml of 
supernatant with 4.0 ml of Instagel (Packard) and counting. Bound 
rad ioac t iv i ty was measured by dissolving the pel lets in 1.0 ml of Soluene-100 
(Packard), mixing with 12 ml of Instagel/1 N HCl (9/1) and counting. The 
samples were counted in a Packard Tricarb l iqu id s c i n t i l l a t i o n counter (model 
460 C). 
Specific [ 3 H ] - ( - ) - Q N B binding was defined as the difference between binding 
in the absence and presence of unlabeled 0.1 μπιοΐ/ΐ (-)-QNB. Binding 
parameters were calculated by subjecting data to a non-linear least-squares 
curve f i t t i n g routine using the Gauss-Newton algorithm (Fletcher and Powell 
1963). Inh ib i t ion curves of agonists were analyzed according to a one and a 
two binding s i te model. Preference was given to a two binding si te model when 
a s ign i f icant diminution in the residual sum of squares was obtained (F-test; 
Ρ < 0.05). I n h i b i t i o n curves of antagonists were f i t t e d according to a one 
binding s i t e model. 
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Protein concentrations were determined by the method of Lowry as modified by 
Peterson (1977) using bovine serum albumin as standard. 
Contraction studies 
Tracheal smooth muscle str ips were contracted with methacholine isotonica l ly 
under a load of 0.5 g in Krebs-Henseleit buffer pH 7.4 (370C) containing 
glucose (1 g/1) and aerated with oxygen-carbondioxide (95/5). After an 
equi l ibrat ion period of 1 h cumulative dose-concentration curves were made 
(Van Rossum 1963). pD2 (-log EC50) values and H i l l coeff ic ients (пн) 
were determined by non-linear regression analysis according to the following 
model : 
E 1 
•-max 1 + 'EC50 " ^ 
using the same computer program as for the radioligand binding studies with 
s l ight modif ications. In t h i s equation С is the concentration of the agonist, 
E is the measured e f f e c t , Emax is the maximal obtainable effect and EC50 
is that concentration producing halfmaximal e f f e c t . From each subject at least 
two tracheal smooth muscle st r ips were mounted and with each s t r i p at least 
three dose-contraction curves were made. From these dose-response curves the 
subjects's mean pD2-value and H i l l coef f ic ient were calculated. 
RESULTS 
Binding paraneters 
Figure 1 shows a representative curve of [3H]-(-)-QNB binding to human 
tracheal smooth muscle membranes. Specific binding was saturable and of high 
affinity. A Scatchard representation of the saturation isotherm (insert) 
pointed to a homogeneous population of binding sites. Binding parameters of 14 
subjects yielded a mean equilibriim dissociation constant (Kj) of 47 ± 4 
pmol/1 and a total receptor density (Ry) of 920 ± 120 fmol/g tissue (wet 
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1 00 1 2 5 1 5 0 1 7Ь 
[ 5 H ] - ( - ) - Q N B free in г тюІЛ 
Fig. 1: Binding of [ 3 H ] - ( - ) - Q N B to membranes of human tracheal smooth 
muscle. Total binding ( · ) and non-specific binding ( A ) , determined in 
the presence of 0.1 μπιοΐ/ΐ (-)-QNB. Insert: Scatchard plot of the 
specif ic binding. 
[ 3 H ] - H - Q N B bound tpmol/g) 
0.4 
200 2 4 0 
Time (minutes) 
Fig. 2: Kinetics of [ 3 H ] - ( - ) - Q N B binding to human tracheal smooth muscle 
membranes. Incubations were carried out at З^С with a [ 3 H ] - ( - ) - Q N B 
concentration of 36 pmol/1 and a tissue concentration of 15 mg/ml. 
Total binding ( · ) and non-specific binding (à ) , determined in the 
presence of 0.1 μπιοΐ/ΐ (-)-QNB was measured up to 240 min. 
Dissociation of [ 3 H ] - ( - ) - Q N B binding (o) was unmasked by the 
addition of 0.1 μπιοΐ/ΐ (-)-QNB. 
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weight) corresponding with 123 ± 16 fmol/mg protein (mean ± SEM). The presence 
of the protease inhibitor phenyl methyl sulfonylfluoride (PMSF, 10"4 mol/1) 
during membrane preparation and incubation had no effect on receptor binding 
parameters. No dependency of affinity or density on postmortem delay was 
observed 2-24 h after death. Similar results were obtained with bovine 
tracheal smooth muscle stored for 24 hours at room temperature (results not 
shown). 
Kinetics of [3H]-(-)-QNB binding 
Specific [3H]-(-)-QNB binding to human tracheal smooth muscle membranes at 
ЗТ'С was slow with an association rate constant of 0.14xl09 (mol/l)"l 
min-l(Fig.2). After 90 min more than 90% of the maximal receptor occupation 
at a free ligand concentration of 36 pmol/1 was observed. Reversibility of 
specific [3H]-(-)-QNB binding was demonstrated by the addition of 0.1 μΐηοΐ/ΐ 
(-)-QNB. 
Dissociation proceeded slowly with a rate constant of 2.72xl0-3min-l. From 
the dissociation and association rate constants a kinetic K^-value of 19 
pmol/1 was calculated. This value agreed well with the K^-values determined 
in equilibrium binding studies. 
Dependency on tissue concentration 
[3H]-(-)-QNB binding was linearly dependent on tissue concentration in the 
range 5-50 mg tissue/ml (free ligand concentration 270 pmol/1; r = 0.99, 
results not shown). 
Stereoselectivity and pharmacological characteristics of specific 
[3H]-(-)-QNB binding 
Figure 3 shows the competition curves of the muscarinic antagonists studied. 
The corresponding inhibition constants (Κή) are listed in Table 1. 
Stereoselectivity was demonstrated in competition experiments with the 
enantiomers of the muscarinic antagonist benzetimide. The biologically active 
dexetimide exhibited a thousandfold lower K-j-value than the far less active 
optical antipode levetimide. Further evidence for a muscarinic nature of the 
binding sites was obtained by competition studies with the experimentally and 
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c l i n i c a l l y e f fect ive bronchodilator ipratropiun bromide (Gross and Skorodin 
1984; Massey and Götz 1985). Ipratropium bromide inhibited specif ic 
[ 3 H ] - ( - ) - Q N B binding at very low concentrations in accordance with known 
potency. Pirenzepine, the selective antagonist at the M-l subclass of 
muscarinic receptors was used to assign the muscarinic receptor population of 
human tracheal smooth muscle as belonging to one of the subclasses M-l or 
M-2. Inh ib i t ion of specif ic [3H]-(-)-QNB binding was best described by 
interact ion with a single class of binding s i tes , indicating the presence of a 
homogeneous receptor population. ТЪе K-¡-values ident i f ied the muscarinic 
receptor population as belonging to the M-2 subtype. 
Agonist binding to muscarinic receptors is generally described by interact ion 
with two major classes of binding s i tes : one with high and one with low 
a f f i n i t y for agonists (Birdsal l et a l . 1978). To investigate the presence of 
such a d i s t r i bu t i on , displacement of specif ic [ 3 H ] - ( - ) - Q N B binding by the 
muscarinic agonists methyl f urtrethonium (MeFur) and methachol ine (MeCh) was 
studied (Fig.4 and Table 2 ) . 
Table 1: Inh ib i t ion constants of muscarinic antagonists for [ 3 H ] - ( - ) - Q N B 
binding to human tracheal smooth muscle membranes. 
K i imol / l ) 
Dexetimide 
Levetimide 
Ipratropium bromide 
Pirenzepine 
1. 
2. 
1. 
2. 
1. 
2. 
1. 
2. 
1.1x10-9 
1.9x10-9 
1.3x10-6 
1.6x10-6 
1.2x10-9 
1.6x10-9 
0.6x10-6 
1.7x10-6 
Inhibition constants (Ki) were determined in [3H]-(-)-QNB 
competition experiments. Duplicate values were obtained from 
different subjects. 
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F ig. 3: 
Fractional specific рн] -(-)-ONB binding 
» dexetimide 
• ipratropiumbromide 
Δ levetimide 
о pirenzepine 
-12 -10 -8 -6 
log antagonist (mol/l) 
Inhibition of specific [3H1-(-)-QNB binding to membranes of human 
tracheal smooth muscle by muscarinic antagonists. The competition 
curves were fitted to a one binding site model. Corresponding 
inhibition constants are listed in Table 1. Eacht point is the mean of 
a duplicate determination from a single subject. Relative SE values 
were less than 5%. 
Fractional specific Рн] - (-) -QNB binding • 
» control 
o .Gpp(NH)p 
( IO - 4 mol /I) 
-6 - 4 -2 
log Methylfurtrethomum (mol/l) 
Fig. 4: I n h i b i t i o n of specif ic [ 3 H ] - ( - ) - Q N B binding to human tracheal smooth 
muscle membranes by methylfurtrethoni urn in the absence ( A ) and 
presence(o) of S'-guanylylimidodiphosphate (Gpp(NH)p). I n h i b i t i o n 
curves were best f i t t e d according to a two binding s i te model (F-test; 
Ρ < 0.05). Each point is the mean of a duplicate determination from a 
single subject. Corresponding Ki-values are l i s t e d in Table 2 
(subject I ) . Relative SE values were less than 5%. 
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Table 2: Binding parameters of muscarinic agonists for human tracheal smooth 
muscle membranes. Effect of 5' -guanylyl imidodiphosphate (Gpp(NH)p). 
Methyl f urtrethom'urn 
Subject I 
Кн K L R H / R L 
(μΜ) (μΜ) (%) 
Subject II 
Control 
+Gpp(NH)p 
(10-4M) 
кн KL 
(μΜ) (μΜ) 
0.6 15 
0.8 12 
Methacholine 
Subject III 
RH/RL 
(%) 
58/42 
40/60 
кн KL 
(μΜ) (μΜ) 
1.6 19 
1.0 14 
Subject IV 
RH/RL 
(%) 
37/63 
26/74 
кн KL RH/RL 
(μΜ) (μΜ) (%) 
Control 
+Gpp(NH)p 
(10-4M) 
2.4 75 
ND 
38/62 2.6 61 19/81 
71 0/100 
Competition curves for [ 3 H ] - ( - ) - Q N B binding were f i t t e d to a model 
of two classes of binding s i tes. Membrane preparation and binding 
experiments were performed in the presence of Ю-1* mol/l PMSF as 
protease i n h i b i t o r except for subject I . I n h i b i t i o n constants of the 
high (Кн) and low ( K L ) a f f i n i t y s i tes are given in μπιοΐ/ΐ. The 
r e l a t i v e proportions (RH/RL) 0 ^ the high and low a f f i n i t y binding 
s i tes are presented as percentage of t o t a l specif ic binding. 
N.D.: not determined 
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I n h i b i t i o n of specif ic [3H]-(-)-QNB binding by MeFur and MeCh was 
s i g n i f i c a n t l y better described by an interaction model with two classes of 
binding sites (F-test; Ρ < 0.05). 
Computerized analysis of binding data pointed to presence of nearly equal 
proportions of high and low a f f i n i t y binding s i t e s . 
The MeFur a f f i n i t y values for both binding sites (0.6-1.6 and 15-19 μηοΐ/ΐ) 
were in the same range as those found in bovine tracheal smooth muscle, i . e . 
0.2-0.3 and 16-18 μπιοΐ/ΐ (Beid et a l . 1980). Since guanosine-S'-triphosphate 
and i t s nonhydrolyzable analogue 5'-guanylyl imidodiphosphate (Gpp(NH)p) have 
been shown to convert muscarinic high a f f i n i t y sites into low a f f i n i t y sites 
(Ehlert et a l . 1981), the ef fect of Gpp(NH)p (IO"4 mol/1) on the i n h i b i t i o n 
of [3H]-(-)-QNB binding by MeFur and MeCh was examined (Fig. 4 and Table 2 ) . 
Gpp(NH)p reduced the r e l a t i v e proportion of high a f f i n i t y s i tes only 
s l i g h t l y . 
Recently, Aronstam and Greenbaum (1984) found evidence that absence of a 
Gpp(NH)p ef fect might be caused by proteolysis during the muscarinic receptor 
binding assay performed at ЗТ'С. A Gpp(NH)p ef fect was demonstrated in the 
presence of the protease inh ib i tor PMSF ( l O ^ m o l / l ) . For t h i s reason, 
agonist binding experiments in subject I I , I I I and IV were carried out in the 
presence of 10"4 mol/1 PMSF thereby also i n h i b i t i n g endogeneous 
acetylcholinesterase (Turini et a l . 1969). I t appeared however that the 
presence of PMSF did not enhance the Gpp(NH)p e f f e c t . 
Methachol ine-induced contraction 
In order to relate binding data to physiological responses, we investigated 
human tracheal smooth muscle contraction by methachol ine (F ig.5) . Although 
MeCh might be hydrolyzed slowly by endogeneous acetylcholinesterase, i t was 
given preference over the non-hydrolyzable MeFur as muscarinic agonist because 
reversal of MeFur-induced contraction by subsequent washings for as yet 
unknown reasons was extremely slow compared to MeCh. MeCh dose contraction 
curves had a H i l l - c o e f f i c i e n t of 1.10 ± 0.04 and a pD2-value of 6.75 ± 0.02 
(mean ± SEM, η = 9 ) . The pD2-value was well within the range given by 
Birdsal l et a l . (1978) in a var iety of other smooth muscle preparations. 
Inh ib i t ion of specif ic [ 3 H ] - ( - ) - Q N B binding by MeCh could be described 
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adequately by interact ion with two classes of binding s i tes . The pKí-values 
i . e . , 4.17 and 5.60, however, were considerably lower than the pD2-value 
derived from the contraction studies. This discrepancy might be explained, as 
has been done in other t issues, by the presence of a large receptor reserve, 
implying act ivat ion of only a small f ract ion of available receptors for 
maximal e f fec t . 
Fractional Fractional inhibition of 
contraction specific P H l - t - l - Q N B 
(·/·) binding (·/.) 
100 
8 0 
6 0 -
40 
2 0 -
0 
ι ι ι ι ι ι ι ι ι ι I — I - ^ r ™ -
-10 -8 -6 - 4 - 2 0 2 
log Methacholme (mol/l) 
Fig. 5: Comparison of the potencies of methacholine in contracting human 
tracheal smooth muscle [ l e f t ordinate ( · ) ] and in displacing specif ic 
[ 3 H Ì - ( - ) - Q N B binding to human tracheal smooth muscle membranes 
[ r i gh t ordinate ( o ) ] . The inh ib i t ion curve was f i t t e d by a two binding 
s i te model. Each point is the mean ± SE from nine subjects (% 
contraction) or the mean of a duplicate determination from subject I I I 
(% i nh ib i t i on ) . Inh ib i t ion constants for [3H]-(-)-QNB binding are 
1isted in Table 2. 
DISCUSSION 
Specific [ 3 H ] - ( - ) - Q N B binding to muscarinic receptors in human tracheal 
smooth muscle membranes appeared to be saturable, revers ib le, stereoselective 
and of high a f f i n i t y . The Kj-value agreed well with those found in bovine 
and canine tracheal smooth muscle (Van Koppen et a l . 1984; Murías et a l . 
1982). 
The binding capacity, however, was smaller than those found in the afore-
f 
/ 
h 
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mentioned species. Although theoretically the low binding capacity might be 
caused by postmortem degradation of receptors, this is not a likely 
explanation because no decline in receptor density was observed 2-24 h after 
death. 
Perry (1980) and Undén et al. (1983) also reported good postmortem stability 
of muscarinic receptor density in hinan brain tissue. When we compared 
muscarinic receptor density and affinity in bovine tracheal smooth muscle, 
stored for 24 hours at room temperature with the binding parameters determined 
in fresh tissue, no significant reduction could be observed. For these 
reasons, the receptor density found postmortem may be regarded as the one 
actually present in the living subject. 
The low receptor density in human tracheal smooth muscle is somewhat 
surprising because it is not accompanied by a diminished sensitivity towards 
muscarinic agonists. Obviously, receptor number is not directly related to 
sensitivity of the contractile response in smooth muscle tissue. This 
contrasts with the generally accepted notion that tissue sensitivity is less 
when receptor number is low. 
Competition of specific [3H]-(-)-QNB binding by muscarinic antagonists and 
agonists satified the criteria of a muscarinic receptor nature. The order of 
muscarinic antagonist potencies was similar to those found in human lung and 
experimental animal respiratory tissue (Raaymakers et al. 1984; Mita et al. 
1982; Beld et al. 1975; Murías et al. 1982). The M-l selective antagonist 
pirenzepine recognized only a homogeneous population of binding sites. Its low 
binding affinity corresponded well with that found in other smooth muscles, 
classifying human tracheal smooth muscle muscarinic receptors as M-2 receptors 
(Hammer et al. 1980; Hammer and Giachetti 1982). 
Inhibition of antagonist binding by agonists was best described by interaction 
of the agonists with high and low affinity binding sites, present in nearly 
equal proportions. This ratio agreed well with those found in bovine and 
canine tracheal smooth muscle (Beld et al. 1980; Murías et al. 1982). The 
proportion of high versus low affinity binding sites was slightly decreased by 
Gpp(NH)p. The effect however was not as distinct as reported by Murías et al. 
(1982) in canine tracheal smooth muscle. Whether autolysis during postmortem 
delay has resulted in a diminished effect of Gpp(NH)p on agonist binding 
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remains to be established. I t should be noted, however, that the effects of 
guanine nucleotides are not uniform in d i f f e r e n t tissues (Ehlert et a l . 1981; 
Burgen 1984). 
Ki-values of MeCh binding to the high and low a f f i n i t y binding sites 
(2.4-2.6 and 75-61 μπιοΐ/ΐ) did not coincide with the ECso-value of 0.18 
μπιοΐ/ΐ for inducing a contract i le response. This discrepancy might be 
interpreted as a consequence of the presence of a large receptor reserve 
(Furchgott and Bursztyn 1967). 
The concept of receptor reserve or spare receptors, however, has been 
challenged recently by comparing contraction data with radioligand binding 
data. Several inconsistencies regarding c o n t r a c t i l e response and receptor 
number before and after i r revers ib le receptor blockade with a lkylat ing 
antagonists were found (Siegel and Triggle 1982); Takeyasu et a l . 1979; 
El-Fakahany and Richelson 1981). 
The question remains which of two binding s i t e s , or both, are responsible for 
the c o n t r a c t i l e response. There is no unanimity with respect to the functional 
ro le of high and low a f f i n i t y agonist binding s i tes (McKinney and Richelson 
1984). Muscarinic receptor activation has several biochemical consequences 
l i k e i n h i b i t i o n of adenylate cyclase, increased phosphatidyl inosi to l turnover, 
Ca2+ mobil izat ion and stimulation of guanylate cyclase. I t has been 
suggested that high and low a f f i n i t y binding sites are involved in these 
processes in a d i f f e r e n t manner (McKinney and Richelson 1984). 
Patients suffering from obstructive lung disease show bronchial 
hyperreact iv i ty to physical, chemical and pharmacological st imul i (Boushey 
et a l . 1980). The fact that the exaggerated bronchomotor response to for 
instance cholinergic agonists can be inhibi ted by atropine and other 
muscarinic antagonists demonstrates the signif icance of the muscarinic 
receptor in bronchial hyperreactiv i ty (Gross and Skorodin 1984). A better 
understanding of muscarinic receptors in hunan airways might lead to better 
therapies for patients suffering from obstructive lung disease. 
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CHAPTER 3 
ß-ADRENOCEPTORS IN HUMAN TRACHEAL SMOOTH MUSCLE: 
CHARACTERISTICS OF BINDING AND RELAXATION 
Chris J. van Koppen, Marcel W. Hermanussen, Kiek N. Ver r i jp , 
Jaap F. Rodrigues de Miranda, Arie J. Beid, Jan-Willem J. Lammersl 
and Cees A.M. van Ginneken 
Departments of Pharmacology and Pulmonary Diseases^, University of Nijmegen 
SUMMARY 
Specific binding of [125i]_(-)_Cya nopindolol to human tracheal smooth muscle 
membranes was saturable, stereoselective and of high a f f i n i t y (K^ = 5.3 ± 
0.9 pmol/1 and R^  = 78 ± 7 fmol/g t issue) . The betai-select ive antagonists 
atenolol and LK 203-030 inhibi ted specif ic [1 2 5 I ]-(-)-cyanopindolol binding 
according to a one binding s i te model with low a f f i n i t y in nearly a l l 
subjects, pointing to a homogeneous ß2-adrenoceptor population. In one 
subject using LK 203-030 a small ßi-adrenoceptor subpopulation could be 
demonstrated. Beta-mimetics; isoprenal ine, fenotero l , salbutamol and 
terbutal ine recognized high and low a f f i n i t y agonist binding s i tes . 
Isoprenaline's рКц- and pKL-values for the high and low a f f i n i t y s i tes 
were 8.0 + 0.2 and 5.9 ± 0.3 respectively. In functional experiments 
isoprenal ine relaxed tracheal smooth muscle str ips having i n t r i n s i c tone with 
a pD2-value of 6.63 ± 0.19. Assuming that the high a f f i n i t y agonist binding 
s i te is responsible for activation of adenylate cyclase, the discrepancy 
between pD2-value and рКн-value may be considered to be a consequence of 
poor coupling between the ß-adrenoceptor and the relaxant system. 
INTRODUCTION 
The airways of asthmatics are abnormally sensit ive to Inhaled i r r i t a t i n g 
substances to which they respond with bronchoconstriction. This bronchial 
39 
Chapter 3 
hyperreact iv i ty is also frequently encountered in patients with chronic 
obstructive bronchit is (1 ) . 
Accordinq to Szentivanyi (2) the basic anomaly in asthma is an inherited or 
acquired p-adrenoceptor dysfunction. A reduced ß-adrenoceptor response in 
airway smooth muscle relaxat ion might be caused by alterat ions at a number of 
loc i in the chain of events between receptor occupation and smooth muscle 
relaxation such as decreased receptor number, changes in the number of high 
and low a f f i n i t y agonist binding s i tes, altered eff icacy in adenylate cyclase 
act ivat ion or deviations in more dista l post-receptor events. 
Or ig inal ly formulated as a mechanism involved in asthma, the ß-adrenoceptor 
theory of Szentivanyi has been considered to be relevant in other (chronic) 
obstructive lung diseases (COLD) as we l l . With [3H]-(-)-dihydroalprenolol as 
radioligand ß-adrenoceptors have been quantitated in lung homogenates of 
patients with COLD and control subjects but no s igni f icant differences in 
receptor a f f i n i t y or number were found (3) . These observations may be taken as 
evidence against Szentivanyi's hypothesis. However, ß-adrenoceptor dysfunction 
might be ref lected in other receptor character ist ics than in antagonist (e .g. 
[3Hl-(-)-dihydroalprenolol) binding. Furthermore, autoradiographic studies 
have revealed that airway smooth muscle ß-adrenoceptors account only for a 
small proportion of to ta l human lung ß-adrenoceptor density (4). An impaired 
ß-adrenoceptor in himan airway smooth muscle might therefore be masked by 
unaltered ß-adrenoceptors in other tissue types in human lung. 
Homogeneous smooth muscle, however, is extremely d i f f i c u l t to isolate from 
intrapulmonary airways. The small dimensions of the bronchi and bronch io l i , 
the heterogeneous composition and the interwovenness of the various tissue 
types within the airway walls hinder to dissect homogeneous airway 
musculature in suf f ic ient amounts for radioligand binding studies. 
Tracheal smooth muscle, however, is re la t i ve ly homogeneous and can be obtained 
in suf f ic ient amounts. For these reasons we preferred to use human tracheal 
smooth muscle to study the airway smooth muscle ß-adrenoceptor population. The 
ß-adrenoceptor population was quantitated by [125i ]-(-)-cyanopindolol 
binding experiments and ident i f ied by inh ib i t ion experiments with ß-adrenergic 
antagonists and agonists. In addit ion, isoprenaline-induced smooth muscle 
relaxation data were compared with i t s binding character is t ics. 
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HETHODS 
Materials 
(-)-Cyanopindolol, [ 1 2 5 l ] , ( [ 1 2 5 I ] - ( - ) - C Y P ] (spec. act. 81 χ 10*2 
Bq/mmol) was purchased from NEN Europe. The fol lowing compounds were g i f t s : 
atenolol , ICI 118,551, (+)- and (-)-propranolol (ICI L t d . , Alderly Park, 
England), salbutamol (Glaxo Group Research, Ware, England), fenoterol and 
(±)-isoprenal ine (Boehringer Ingelheim, FRB), terbutal ine (Astra 
Pharmaceutical Production, Sò'dertalje, Sweden) and LK 203-030 (Sandoz, Basel, 
Switzerland). (+)-Propranolol, bovine serum albumin, phenylmethylsulfonyl-
f luor ide (PMSF) and 5'-guanylylimidodiphosphate (Gpp(NH)p) were purchased from 
Sigma Chemical Company (St. Louis, MO, USA). 
Membrane preparation 
Human tracheae were received with a post-mortem delay of 2 hours (n = 4 ) , 3-6 
hours (n = 7) , 7-16 hours (n = 9) and 17-24 hours (n = 10). The mean 
postmortem delay was 13 ± 10 hours (SE). The time span between death and body 
ref r igerat ion was 1-3 hours. The mean age of subjects was 57 ± 22 years (SE), 
ranging from 3 to 80 years. Material used was from subjects free of known 
history of respiratory or thyroid disease and none of them had received 
p-adrenergic or glucocort icoid therapy. Human tracheal smooth muscle was 
prepared and homogenized as described in chapter 2 (5). The resul t ing 100,000 
9max membrane pel le t was stored at -2CPC for periods no longer than one 
week. 
Receptor Assay 
Membrane pel lets were resuspended in modified Krebs-Ringer buffer pH 7.0. 
Separation of membrane bound rad ioact iv i ty was achieved by centr i fugat ion or 
when indicated by f i l t r a t i o n through Whatman GF/C f i l t e r s . Polypropylene 
microcentrifuge tubes (1.5 ml) or glass tubes (6 ml) ( f i l t r a t i o n experiments) 
received consecutively 70 μΐ [125i ]-(-)-CYP in Krebs-Ringer buf fer , 70 μΐ 
Krebs-Ringer buffer with or without competing ligand and 700 μΐ t issue 
homogenate corresponding with 10-30 mg t issue. Experiments with isoprenaline 
were done in the presence of 1 mmol/1 ascorbic acid to counteract oxydation of 
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the catechol moiety and PMSF to i n h i b i t endogeneous proteolyt ic a c t i v i t y . 
For equil ibrium binding experiments concentrations of [125i].(-)_CYP varied 
from 0.5 to 50 pmol/1 and for inh ib i t ion experiments a fixed concentration 
between 10 and 25 pmol/1 was used. Incubations were performed at З^С for 90 
min while rotat ing at 2 rpm (microcentrifuge tubes) or gently shaking (glass 
tubes). Incubations were terminated by centr i fugat ion at 18,000 %
ΆΧ
 for 15 
min in a Heraeus-Christ Hâmofuge or by d i l u t i on with 4 ml ice-cold 
Krebs-Ringer buf fer , followed by f i l t r a t i o n through Whatman GF/C f i l t e r s and 
washing twice with 4 ml ice-cold Krebs-Ringer buffer. In f i l t r a t i o n assays 
[ 1 2 5 I ] _ ( _ ) _ C Y P bound was kept below 10% of added l igand. Specific 
[125i]_(_)_cYP binding was defined as the difference between binding in the 
absence and presence of 1.0 μιποΐ/ΐ (±)-propranolol. Routinely, binding and 
i n h i b i t i o n experiments were performed using the centr i fugation assay. In a 
l imited number of cases with unfavourable specif ic - nonspecific binding 
rat ios the f i l t r a t i o n assay was used. Experimental data were analyzed and 
binding parameters calculated by a non-linear least-squares curve f i t t i n g 
routine (6). Each i n h i b i t i o n curve was analyzed according to a one and two 
binding s i te model. Preference was given to a two binding si te model when a 
s ign i f icant diminution in the residual sun of squares was reached (F-test; Ρ < 
0.05). The mean Kj-value and i t s SEM were calculated as described by De Lean 
et a l . ( 7 ) . Data points in inh ib i t ion experiments are in duplicate. For the 
salbutamol and terbutal ine inh ib i t ion studies the amount of tissue received 
was too small for duplicate measurements. In three control i n h i b i t i o n 
experiments the intra- indiv idual variat ion in binding parameters was found to 
be smaller than that between subjects. Protein concentration was determined by 
the method of Lowry as modified by Peterson (8) using bovine serun albumin as 
standard. 
Relaxation studies 
Tracheal smooth muscle st r ips were mounted under a load of 0.5 g in 
Krebs-Henseleit buffer pH 7.4 containing 5 mmol/1 glucose and gassed with 
O2/CO2 (95/5). Following an equi l ibrat ion period of at least one hour 
preparations were contracted with methacholine to test the responsiveness of 
the s t r i p s . Then, after extensive washing, isotonica l ly cumulative 
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isoprenaline dose-relaxation curves were made without precontraction by 
methachol ine. Isoprenaline solutions contained б nmol/l ascorbic acid to 
counteract oxydation of the catechol moiety. From each patient at least two 
tracheal smooth muscle st r ips were mounted and with each s t r i p at least two 
dose-response curves were made. From these curves pD2-values and H i l l 
coeff ic ients were calculated as described in chapter 2 (5). 
RESULTS 
Binding parane ter s 
Binding of the ß-adrenergic radioligand [125]_(_)_ςγρ to human tracheal 
smooth muscle membranes was saturable and of high a f f i n i t y (Fig. 1). 
Computerized analysis of binding data of 25 subjects showed a mean 
dissociation constant (Kj) of 5.3 ± 0.9 pmol/1 (SEM) and a receptor density 
(Ry) of 78 ± 7 fmol/g t issue, corresponding with 5 ± 1 fmol/mg protein. 
Binding parameters did not vary with postmortem delay up to 24 hours. 
("5U-(-l-CVP binding (fmol/g] . 
bvund/frM 1 
20 
10 20 30 iO SO 60 
('"іЫ-1-CYP liée Ipmol/ll 
Fig. 1: Binding of [ l 2 5 l ] - ( - ) -CYP to human tracheal smooth muscle 
membranes. Total binding (o) and nonspecific binding (Δ) were 
determined in the absence and presence of 1.0 μηοΐ/ΐ (±)-propranolol 
respectively. Insert : Scatchard plot of the specif ic 
[ 1 2 5 I ]-(-)-CYP binding. 
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S imi lar ly , «d- and Rj-values for bovine tracheal smooth muscle stored 24 
hours at room temperature were identical to those in fresh t issue. 
[ 1 2 5 I ] _ ( _ ) _ C Y P binding to human tracheal smooth muscle membranes was 
l i n e a r l y dependent on tissue concentration between 5 and 50 mg at a free 
ligand concentration of 5.8 pmol/1 (r = 0.99). The time course of specif ic 
[ 1 2 5 I ] _ ( _ ) _ C Y P binding at З^С was followed for 300 min at a free 
[ 1 2 5 I ] _ ( _ ) _ C Y P concentration of 5.8 pmol/1. Association of [1 25l]-(-)-CYP 
t o specif ic binding sites occurred with a rate constant of 2.3x10^ 
( m o l / l ) " l m i n - l . At 90 min more than 90% of maximal receptor occupation at 
that concentration was observed. Dissociation of specif ic binding which was 
unmasked by 1.0 nmol/l (±)-propranolol appeared to be extremely slow: after 
205 min only 10% displacement was observed. 
Antagonist competition studies 
Stereoselect iv i ty of specif ic [1Z 5 I]-(-)-CYP binding to human tracheal 
smooth muscle membranes was demonstrated by competition experiments with (+)-
and (-)-propranolol (Fig. 2; Table 1 ) . (+)-Propranolol appeared to be a 
100-fold less potent than (-)-propranolol in competing for [ 1 2 5 I ] _ ( _ ) _ C Y P 
specif ic binding s i t e s . The inh ib i t ion constants of both enantiomers agreed 
well with l i t e r a t u r e values (9, 10). 
To reveal any presence of ßj-adrenoceptors, competition experiments with 
selective ßj-adrenergic antagonists were performed. Atenolol , having a 20-
to 40-fold higher a f f i n i t y for ßi-adrenoceptors than for ß2-adrenoceptors 
produced inh ib i t ion curves which could be f i t t e d adequately by a one binding 
s i te model with high Ki-values (Fig. 2; Table 1) , typical for ßj-adreno-
ceptors (11, 12). The monophasic inh ib i t ion curves of atenolol were indicat ive 
for the absence of ß^-adrenoceptors within detection l im i t s . To disclose a 
ßl-adrenoceptor population of less than 10% with certa inty more selective 
ßl-antagonists are needed (7 ) . Recently, the ßi-antagonist LK 203-030 
reported to have a 500- to 1000-fold se lec t i v i t y became available (13). 
Inh ib i t ion of [ 1 2 5 I ] _ ( _ ) _ C Y P binding by LK 203-030 showed a small 
ßl-adrenoceptor population of (7 ± 1)% in tracheal smooth muscle of one 
subject (F ig. 3) . "me Ki-values ( i . e . 53 ± 7 nmol/1 and 9.3 + 0.7 μπιοΐ/ΐ, 
mean ± SEM.) correspond well with those reported in rat kidney (13) ( i . e . 25 
nmol/1 and 16 μηιοΐ/ΐ). 
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fractional specific [ '" l l - l - l -CYP binding 
-4 -2 
log antagonist (mol/l) 
2: Inh ib i t ion of specif ic [^25! ]-(-)-CYP binding to human tracheal 
smooth muele membranes by (- ) -propranolol , (+)-propranolol and 
atenolol . Each point is the mean of a duplicate measurement from one 
subject. Relative SE values were less than 5%. The competition curves 
could be f i t t e d adequately by a one binding s i te model. Corresponding 
K^-values are l i s ted in Table I . 
spec 
150 
fie D25l] - ( - ) -CYP binding (fmol / g ) 
100 
50-
- one binding $ite model 
-two binding site model 
-10 -9 -6 -5 -4 -3 -2 -1 
log LK 2 0 3 - 0 3 0 ( m o l / l ) 
3: Inh ib i t ion of specif ic [1 2 5 I ]-(-)-CYP binding to human tracheal 
smooth muscle membranes by the ßi-select ive antagonist LK 203-030. 
Each point is the mean of three f i l t r a t i o n experiments. Relative SE 
values were less than 55!. Binding parameters are given in the tex t . 
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In two other subjects, also studied in t r i p l i c a t e , no evidence for the 
presence of a ßi-adrenoceptor population could be found. (Ki-values of 6.4 
and 21.3 μπιοΐ/ΐ). 
Table 1: Inh ib i t ion constants of p-adrenergic antagonists for [125i]_(_)_cYP 
binding to human tracheal smooth muscle membranes from d i f f e r e n t 
subjects. 
Ki (mol/1) 
(-)-propranolol 0.37 χ 10-9 
0.40 χ 10-9 
(+)-propranolol 59.5 χ Ю - 9 
50.9 χ 10-9 
atenolol 6.8 χ 10-6 
5.6 χ 10-6 
8.2 χ 10-6 
Table 2: Binding parameters of p-adrenergic agonists for human tracheal smooth 
muscle membranes from d i f ferent subjects. 
isoprenaline 
fenoterol 
salbutamol 
terbutaline 
KH (nmol/1) 
5.9 
13.5 
10.3 
14.0 
2.9 
7.2 
15.1 
14.1 
21.4 
38.5 
KL (μΠ10ΐ/1) 
0.9 
0.5 
2.2 
1.9 
1.7 
0.7 
1.3 
0.8 
5.5 
3.7 
RH (Χ) 
40 
36 
39 
33 
18 
43 
17 
24 
23 
38 
Κμ and KL refer to high and low a f f i n i t y binding constants 
respectively. Ttie Rn-value represents the high a f f i n i t y binding as 
percentage of specific [125i]_(_)_cYp binding. 
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Agonist competition studies 
ß-Adrenergic agonist binding sites were studied in inh ib i t ion experiments with 
the f u l l agonist isoprenaline and the ß2 " s e l e c t i ve (par t ia l ) agonists 
fenotero l , salbutamol and terbutal ine. The inh ib i t i on curves of a l l agonists 
had a biphasic character indicating the presence of high and low a f f i n i t y 
agonist binding si tes (Fig. 4; Table 2) . 
In the presence of Ю - 4 mmol/1 Gpp(NH)p a steepening of the isoprenaline 
i n h i b i t i o n curves was observed. Complete conversion of high a f f i n i t y binding 
sites into low a f f i n i t y binding s i t e s , however, was found only in two of the 
four subjects studied (results not shown). 
fractional specific [°*n-(->-CYP binding 
IO--
-6 -Í 
log agonist [mol/l] 
Fig. 4: Inh ib i t ion of specif ic [ l 2 5 l ] - ( - ) -CYP binding to human tracheal 
smooth muscle membranes by ß-adrenergic agonists. The curves could be 
f i t t e d s ign i f i can t l y better by a two binding s i te model. Data points 
are the mean of duplicate measurements (isoprenaline and fenotero l , 
SE values less than 5%) or single measurements (salbutamol and 
terbuta l ine) . Corresponding Ki-values are l i s ted in Table 2. In case 
of fenoterol the f i l t r a t i o n assay was used. 
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Tracheal snooth muscle relaxation 
To investigate the relat ionship between ß-adrenoceptor occupation and the 
physiological e f f ec t , we studied isoprenaline-induced relaxation of human 
tracheal smooth muscle. No uptake inh ib i tors were applied to the organ bath. 
Zaagsma et a l . (14) ear l ie r presented evidence for the absence of neuronal and 
extra-neuronal uptake of isoprenaline in human tracheal smooth muscle s t r i ps . 
Isoprenaline relaxed tracheal smooth muscle st r ips having in t r ins ic tone with 
a pD2-value of 6.63 ± 0.19 and a H i l l coeff ic ient of 1.07 ± 0.05 (N=5, mean 
± SEM). No dependency of these parameters on postmortem delay up to 24 hours 
was found. Oxydation of isoprenaline was not responsible for the re la t i ve l y 
low pD2-values since in control experiments the presence of 1 mmol/1 
ascorbic acid in the organ bath did not change the posit ion of the relaxation 
curves. 
DISCUSSION 
Specific [ 1 2 5 I ] _ ( _ ) _ C Y P binding to human tracheal smooth muscle membranes 
sat is f ied the c r i t e r i a for ß-adrenoceptor binding. Binding was saturable, 
stereoselective and of high a f f i n i t y . The «¿-value of [ l 2 5 l ] - ( - ) -CYP 
binding was similar to those determined in bovine and canine tracheal smooth 
muscle membranes (15, 16). The low receptor density was a main obstacle in a 
systematic characterization of the ß-adrenoceptor in hunan airway smooth 
muscle and in complex experiments l i ke those with Gpp(NH)p, pooling of t issue 
would be preferable. This consideration, however, was in con f l i c t with our 
main interest to study the variat ion in binding character ist ics between 
d i f ferent subjects. 
[ 1 2 5 I ] _ ( . ) _ C Y P binding showed a normal d i f fus ion-contro l led association rate 
(17) and an incubation time of 90 min ensured more than 90% equi l ibr iun at 5.8 
pmol/1 [ l ^ S i j . f . j . c Y p , Dissociation proceeded much slower than one would 
expect on basis of the equil ibrium Kj-value and ko n-value. We have no 
sat isfactory explanation for th is phenomenon. 
The pKi-values of (-)-propranolol and atenolol ( i . e . 9.4 and 5.2 
respectively) are in agreement with pAg-values found in relaxation studies 
of human bronchial s t r ips ( I . e . for (+)-propranolol 9.3 ± 0.4 and for atenolol 
48 
Chapter 3 
5.3 ± 0.4) (18). 
The inh ib i t ion experiments with atenolol and LK 203-030 provided evidence for 
an (almost) homogeneous ßj-adrenoceptor population in human tracheal smooth 
muscle and support functional data from relaxation studies (14, 18). Tlie 
presence of ßj-adrenoceptors has been connected with adrenergic 
innervation. According to Arië'ns and Simonis (19) ßi-adrenoceptors are meant 
for the neurotransmitter noradrenaline and ß2-adrenoceptors for the hormone 
adrenaline. Indeed, human airway smooth muscle appears to be almost devoid of 
adrenergic innervation. Using histological techniques some investigators (20, 
21) found a few catechol ami ne-contai η ing nerve f ibers innervating human airway 
smooth muscle whereas others (22, 23) were not able to detect any. Electr ic 
f i e l d stimulation experiments also indicate no or minimal contr ibut ion of 
adrenergic f ibers in airway smooth muscle relaxation (22, 24, 25). 
Isoprenaline recognized high and low a f f i n i t y agonist binding sites in human 
tracheal smooth muscle with K^-values similar to those described in other 
tissues (9, 26, 27). The steepening of the i n h i b i t i o n curve in the presence of 
Gpp(NH)p is generally interpreted as a conversion of the high a f f i n i t y state 
of the ß-adrenoceptor into the low a f f i n i t y state (28). Data analysis of the 
experiments were in accordance with th is interpretat ion in two subjects. In 
the two other subjects, conversion was incomplete. In rat lung membranes 
Gpp(NH)p completely converts high a f f i n i t y sites into low a f f i n i t y si tes but 
only when proteolyt ic ac t i v i t y is counteracted (27). In the absence of 
protease inhib i tors Gpp(NH)p is less e f fec t ive. In our studies the protease 
inh ib i tor PMSF had no ef fect indicating that proteolyt ic ac t i v i t y inhibi ted by 
PMSF is not responsible for the incomplete conversion. 
The (par t ia l ) ß2-adrenergic agonists fenotero l , salbutamol and terbutal ine 
d i f ferent iated between high and low a f f i n i t y binding s i tes . The percentages of 
to ta l receptors recognized in the high a f f i n i t y state as well as the Кі_/Кн 
r a t i o s did not d i f f e r markedly among these compounds. Comparison of the 
i n t r i n s i c a c t i v i t i e s has not yet been made in human airway smooth muscle 
s t r i p s . Kent et a l . (26) noticed in frog erythrocytes that К(_/Кн- and 
URn-values rat ios of ( p a r t i a l ) ß-adrenergic agonists correlate well with 
the i r potency in maximal act ivat ion of adenylate cyclase. On basis of the 
binding parameters of isoprenaline, fenoterol , salbutamol and terbutal ine in 
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human tracheal smooth muscle membranes, marked differences between the 
i n t r i n s i c a c t i v i t i e s of these agonists in adenylate cyclase activation are not 
to be expected. 
The high a f f i n i t y agonist binding s i te is generally regarded as the one 
pr imar i ly involved in adenylate cyclase a c t i v a t i o n . Isoprenaline's рКн-value 
( i . e . 8.0 ± 0.2) was s i g n i f i c a n t l y higher than i t s pD2-value for smooth 
muscle relaxation ( i . e . 6,63 ± 0,19), The discrepancy can be explained by 
assuming poor coupling between receptor and biochemical l inks involved the 
relaxant response. A l t e r n a t i v e l y , comparing the pD2-value with the 
рК|_-value of 5.9 ± 0.3 by assuming act ivat ion of adenylate cyclase through 
the low a f f i n i t y binding s i te is appealing but t h i s is not in accordance with 
current concepts. 
Recently, Peterson et a l . (29) and Cerrina et a l . (30) found a marked decrease 
in isoprenaline s e n s i t i v i t y in bronchial s t r i p s of asthmatics. This may be 
taken as evidence for impaired β-adrenoceptor function although reduced 
isoprenaline s e n s i t i v i t y might equally well be based on higher levels of 
i n t r i n s i c tone or altered post-receptor mechanisms. A ß-adrenoceptor defect in 
a s t r i c t sense in asthmatic airway smooth muscle remains to be established. 
More elaborate studies of the ß-adrenoceptor and post-receptor mechanisms in 
airway smooth muscle of patients with obstructive airway disease w i l l be 
needed. 
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AUTORADIOGRAPHIC VISUALIZATION OF MUSCARINIC RECEPTORS 
IN BOVINE AND HUMAN BRONCHI 
Chris J. van Koppen, W. Matthijs Blankesteijn, 
André B.M. Klaassenl, Jaap F. Rodrigues de Miranda, Arie J. Beid 
and Cees A.M. van Ginneken 
Departments of Pharmacology and Otorhinolaryngologyl, University of Nijmegen 
SUMMARY 
To visualize muscarinic receptors in bovine and human bronchi, two 
autoradiographic methods were evaluated which permit d i rect loca l iza t ion of 
tissue labe l l ing . 
Cryostate sections of bovine and human bronchi were f ixed in 0.5% 
g lutar aldehyde in Krebs-Ringer buffer pH 7.0 for 30 min at CPC, washed in 
Krebs-Ringer buffer for 20 min at CPC and incubated with 
[3H]-(-)-Quinucl id inyl benzilate ([3H]-(-)-QNB) for 90 min at 370C. 
Specific [ 3 H ] - ( - ) - Q N B binding to tissue sections was saturable and of high 
a f f i n i t y . I ts a f f i n i t y value was not influenced by f i x a t i o n . 
For autoradiography labelled tissue sections were dipped in photographic 
emulsion or covered with str ipping f i l m . The corresponding autoradiographs 
demonstrated identical receptor d is t r ibu t ions . 
Bovine autoradiographs showed a dense specif ic label l ing of bronchial 
musculature and less s i l ver grains over parasympathetic ganglia and nerve 
bundles. Specific label l ing of submucosal glands, epithelium and subchondrial 
blood vessels could not be observed. 
Muscarinic receptors in human bronchi were located in submucosal glands, 
parasympathetic gangl ia, smooth muscle ce l ls and nerve bundles. Epithel i un and 
subchondrial located blood vessels were devoid of specif ic labe l l i ng . 
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INTRODUCTION 
Muscarinic receptors play an important role in human airway smooth muscle 
contraction and submucosal gland secretion. Acetylcholine-mediated 
bronchospasm is relieved by muscarinic antagonists like atropine, and 
cholinesterase-poisons cause massive fluid production in lunq which is 
antagonized by atropine. Patients with asthma and chronic obstructive 
bronchitis suffer from bronchospasm and enhanced mucus production (American 
Thoracic Society 1962). An increased sensitivity of muscarinic receptors In 
human airways has been proposed as an underlying mechanism (see Boushey et 
al. 1980, for a review). Using radioligand binding techniques, we are 
measuring muscarinic receptors in segmental bronchial tissue homogenates of 
patients with chronic obstructive bronchitis. Segmental bronchial tissue is 
composed of various tissue types including smooth muscle cells, submucosal 
glands and blood vessels. We therefore wished to determine the muscarinic 
receptor distribution in human bronchial tissue. To locate receptors 
autoradiographical ly, generally, radioligands are used which bind reversible 
and with moderate affinity. As a consequence precautions have to be taken to 
minimize translocation of radioligand from the receptor during exposure. Such 
labelled tissue sections are best apposed to dry emulsion-coated coversiips 
(Young and Kuhar 1979). After exposure, covers! ips are slightly bent away from 
tissue sections, processed and finally re-apposed over tissue sections. Due to 
the relatively high background, the emulsion-coated coverslip method can only 
be applied when high receptor densities are involved. 
To elucidate the distribution of the small muscarinic receptor populations in 
human bronchi, we preferred a more appropiate autoradiographic method. In 
theory, the affinity of the radioligand [3H]-(-)-Quinuclidinyl benzilate 
([3H]-(-)-QNB) for muscarinic receptors is sufficiently high to permit 
dipping of labelled tissue sections directly in liquid photographic emulsion 
or to cover labelled tissue sections with stripping film without notable 
dissociation of radioligand from receptor. With these techniques, histologic 
and photographic images coincide permanently and localization of small amounts 
of labelling may be ascertained. 
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In the present study, we investigated the r e l i a b i l i t y of the dipping and 
str ipping f i l m technique in bovine bronchi where r e l a t i v e l y high receptor 
concentrations are known to be present, and applied them in hunan bronchi. 
MATERIALS AND METHODS 
Tissue preparations 
Bovine lung was obtained from the slaughterhouse and transported on ice to the 
laboratory within 2-3 hours. Lobes of human lung were received after 
thoractomy of 6 patients ( a l l males, 55 to 74 years of age) undergoing surgery 
for lung carcinoma and were transported on ice to the laboratory within 15-30 
min. None of the patients had obstructive airway disease. Segmental bronchi of 
both species were frozen in isopentane which was cooled in l i q u i d nitrogen and 
stored at -80PC. Specimen were mounted on a block holder with 
carboxymethylcellulose. Cryostate tissue sections (10 μιπ) were cut at -20PC 
and thaw-mounted onto chrome-alun gelatinized microscope s l ides. After storage 
for 16-90 hours at -8CPC, slides were warmed up during 75 min at room 
temperature. To preserve tissue i n t e g r i t y , i t was necessary to f i x tissue 
sections in 0.5% glutaraldehyde in Krebs-Ringer buffer pH 7.0 at OPC for 30 
min, followed by washing twice for 10 min in Krebs-Ringer buffer at (PC. 
Thereafter, sections were used d i r e c t l y in radioligand binding studies. 
Muscarinic receptor binding in bronchial t issue homogenates of both species 
was also investigated by preparing a crude 100,000 g membrane pe l le t as 
described in chapter 2 (Van Koppen et a l . 1985). 
Radioligand binding studies to slide-mounted tissue sections 
For concentration-dependent binding experiments sl ides bearing 9-18 tissue 
sections were incubated at 370C for 90 min in the Krebs-Ringer buffer 
containing [3H]-(-)-QNB (spec. act . 123 χ I O 1 0 Bq/mmol, NEN Europe) 
concentrations ranging from 5 to 1250 pmol/1. Adjacent sections were incubated 
simultaneously in the presence of 0.1 μΐηοΐ/ΐ unlabelled (-)-QNB ( g i f t from 
Dr. G. Lambrecht, Frankfurt/Main) for measuring nonspecific binding. Following 
incubation and washing in Krebs-Ringer buffer twice for 5 min (ЗТ^) to reduce 
nonspecific binding, sections were rinsed in d i s t i l l e d water for 5 min at room 
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temperature to remove salts and then dried at room temperature. Slides were 
broken and transferred to counting v ia ls . After dissolving tissue sections in 
1.0 ml of Soluene-100 (Packard) 12 ml of Instagel (Packard)/1N HCL (9/1) was 
added and r a d i o a c t i v i t y counted in a Packard Tricarb l iqu id s c i n t i l l a t i o n 
counter (model 460 C) with standard deviations less than 7%. 
Total r a d i o a c t i v i t y was corrected for r a d i o a c t i v i t y present in glass-slides 
alone (approximately 6-8 cpm). Free concentration of [ 3 H ] - ( - ) - Q N B was 
determined by mixing 500 μ! of incubation medium with 4.0 ml of Instagel 
followed by counting. Binding parameters were calculated using a non-linear 
least-squares curve f i t t i n g routine (Fletcher and Powell 1963). 
Autoradiography 
For autoradiography sl ides bearing alternate sections were incubated with 
150-250 pmol/1 [ 3 H ] - ( - ) - Q N B in the absence and presence of 0.1 μιηοΐ/ΐ 
unlabelled (-)-QNB. After incubation, washing and drying slides were dipped 
d i r e c t l y in I l f o r d K5 photographic emulsion (d i luted with d i s t i l l e d water 1/1, 
v/v) at about SiPC and dried v e r t i c a l l y at room temperature for 3-4 hours. 
Labelled tissue sections from the same tissue specimen were also covered with 
a Kodak AR-10 str ipping f i l m section soaked in d i s t i l l e d water for 2 min 
(18-2CPC). After drying overnight, the ends of the str ipping f i l m at the back 
of the sl ides were f i r m l y glued to the glass with nai l polish to prevent 
loosening of the f i l m during further processing. After an exposure for 2-20 
weeks at -2CPC the I l f o r d K5 emulsion and Kodak AR-10 str ipping f i l m were 
developed. I l f o r d K5 emulsion was developed in amidol for 8 min, rinsed in 
d i s t i l l e d water for 15 sec, f ixed in sodiumthiosulphate (30%) for 1 min and 
washed in d i s t i l l e d water for 15 min. The Kodak AR-10 str ipping f i l m was 
developed in Kodak D-19 developer for 4 min, rinsed in d i s t i l l e d water for 30 
sec, f ixed in Kodak F-24 f i x e r for 2 min and washed in d i s t i l l e d water for 3 
min. Tissue was stained with Methylgreenpyronin (1%). 
Cholinesterase staining 
Cholinesterase staining of unfixed cryostate t issue sections was performed 
according to the acetylthiocholine method of Koelie and Friedenwald (Thompson 
1966). B r i e f l y , t h i s staining method comprises the following reactions: 
acetylthiocholine is hydrolyzed by acetylcholinesterase, and in the presence 
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of copper glycinate, copper thiochoiine is produced. Copper thiochoiine is 
then converted by ammonium sulfide to copper sulfide which precipitates as 
dark brown deposits. 
RESULTS 
1. Concentration-dependent binding experiments 
Specific binding of [ 3 H ] - ( - ) - Q N B to human segmental bronchial t issue 
sections was saturable and of high a f f i n i t y (F ig. 1). I ts a f f i n i t y value (Kj 
of 40 ± 9 pmol/1 [n = 4 ] ) agreed well with that found in the bronchial t issue 
homogenates (Kj of 39 ± 3 pmol/1 [n = 10 ] ) . The same was true for bovine 
bronchial tissue (Kj values of 50 ± б vs 64 ± 7 pmol/1). Fixed and non-fixed 
tissue sections demonstrated similar [ 3 H ] - ( - ) - Q N B binding parameters. 
['Hl-(-)-QNB bound (fmol/coupi) 
05 10 , 15 
ΓΗΜ-Ι-ΟΝΒ tree (пгтюІЛІ 
Fig. 1: Binding of [3H]-(-)-QNB to human bronchial tissue sections. 
Total binding (o) and nonspecific binding (Δ) assessed in the presence 
of 0.1 pmol/l unlabelled (-)-QNB. Insert: Scatchard plot of specific 
binding. 
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2. Kinetics of [3H]-(-)-QNB binding 
At a [3H]-(-)-QNB concentration of 150 pmol/1, saturation of specific 
binding to himan segmental bronchial tissue sections was reached within 90 min 
and remained constant for at least 2 hours thereafter (Fig. 2). Dissociation 
of specific [3H]-(-)-QNB binding appeared to be slow with a ti/2 of 161 ± 
19 min (η = 3). The stability of the receptor-radioligand complex allows 
extensive washing, thus reducing nonspecific binding without affecting 
specific binding notably. 
To assess the absence of deleterious effects of the emulsion on specific 
[3H]-(-)-QNB binding, labelled bovine tissue sections were immersed in 
Ilford K5 emulsion for 5 min at ЗТ^С which is much longer than in the normal 
dipping procedure. Bound [3H]-(-)QNB remained the same for this period 
indicating that Ilford K5 emulsion does not affect [3H]-(-)-QNB binding. 
ftfl-H-QNB bound llmol/coupe) 
0 3 -
"[ | 
30 60 90 120 150 ISO 210 240 
time (mm) 
Fig. 2: Assocation (o) and dissociation (·) of specific [3H]-(-)QNB binding 
to human bronchial tissue sections at a free radioligand concentration 
of 150 pmol/1 at ЗТ'С. At time intervals indicated, [3H]-(-)-qNB 
binding was determined after a brief wash of 1 min at З^С in 
Krebs-Ringer buffer. 
Dissociation of specific binding was unmasked by addition of 0.1 
nmol/l (-)-QNB. 
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3. Autoradiography 
3.1 Bovine bronchi 
After 2-10 weeks of exposure, autoradiographs of dipped bovine tissue sections 
showed a dense labelling of bronchial musculature (Fig. ЗА) with negligible 
nonspecific labelling (Fig. 3B). A longer exposure time revealed some specific 
labelling of peribronchial nerve bundles and parasympathetic ganglia (Fig. 4A 
and B). Connective tissue adjacent to the smooth muscle layer contained 
negligible labelling. Submucosal glands, epithelium and subchondrial blood 
vessels had no specific labelling. 
The stripping film autoradiographs gave an identical receptor distribution and 
did not show translocation of radioligand from receptor. 
3.2 Human bronchi 
Stripping film autoradiographs were photographed at very high magnification to 
visualize the small muscarinic receptor populations. Fig. 5 shows a partial 
view of a human bronchial tissue section depicting various tissue components. 
Muscarinic receptors appeared to be located in submucosal glands (Fig. 6A and 
B), smooth muscle tissue (Fig. 7A and B) and nerves (Fig. 8A and B). If 
parasympathetic ganglia were encountered they also showed the presence of 
muscarinic receptors (Fig 9A and B). Epithelium and subchondrial blood vessels 
were devoid of specific labelling. Autoradiographs of dipped tissue sections 
demonstrated a similar receptor distribution. The tissue sections, however, 
suffered from a damaged morphology. 
4. Cholinesterase staining 
Cholinesterase staining of bovine and human bronchial tissue sections 
confirmed the autoradiographic results. In bovine bronchi only the smooth 
muscle layer appeared to be innervated by cholinesterase-containing nerves 
whereas in human bronchi cholinergic nerve f i b r e s were located in submucosal 
glands and smooth muscle c e l l s . In both species, epithelium and bronchial 
blood vessels were devoid of cholinergic innervation. 
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Fig. 3: Autoradiographs of dipped bovine bronchial t issue sections after 
incubation in 250 pmol/1 [3H]-(-)QNB in the absence (A) and presence 
(B) of 0.1 μπιοΐ/ΐ (-)-QNB and exposure for 10 weeks. 
Abbreviations: SM = smooth muscle; GL = submucosal gland; EP = 
epithelium and С = c a r t i l a g e . Scale bar 72 μπι. 
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Fig. 4: Localization of muscarinic receptors in bovine peribronchial 
parasympathetic ganglion and nerve bundle. After incubation in 250 
pmol/1 [3H]-(-)-QNB in the absence (A) and presence (B) of 0.1 
μηποΐ/ΐ (-)-QNB, tissue sections were dipped in Ilford K5 photographic 
emulsion and exposed for 16 weeks. Scale bar 36 μηι. 
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Fig. 5: Photomicrograph of a human bronchial t issue section covered with Kodak 
AR-10 str ipping f i l m . Circles 1 and 2 indicate the areas of submucosal 
glands and smooth muscle tissue which are magnified in figures 6A and 
7A. 
Abbreviations: SM = smooth muscle; GL = submucosal gland; EP = 
epithelium; С = cart i lage and N = nerve. Scale bar 200 μιη. 
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Fig. б: Localization of muscarinic receptors in human bronchial submucosal 
glands. "A" is a deta i l from c i r c l e 1 in Fig. 5. Incubation was done 
in 150 pmol/1 [3H]-(-)QNB, in the absence (A) and presence (B) of 
0.1 μΐηοΐ/ΐ (-)-QNB. Exposure was 5 months. Scale bar 14 μΐη. 
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Fig. 7: Localization of muscarinic receptors in human bronchial smooth 
muscle. "A" is a deta i l from c i r c l e 2 in Fig. 5. Incubation was done 
in 150 pmol/1 [ 3 H ] - ( - ) - Q N B , in the absence (A) and presence (B) of 
0.1 μπιοΐ/ΐ (-)-QNB. Exposure was 5 months. Scale bar 14 μπι. 
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Fig. 8: Localization of muscarinic receptors in human peribronchial nerve. 
Tissue sections were incubated in 150 pmol/1 [ 3 H ] - ( - ) - Q N B , in the 
absence (A) and presence (B) of 0.1 μίποΐ/ΐ (-)-QNB, and covered with 
Kodak AR-10 str ipping f i l m . Exposure 5 months. Scale bar 11 μπι. 
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Fig. 9: Localization of muscarinic receptors in human peribronchial 
parasympathetic ganglion. Tissue sections were covered with Kodak 
AR-10 str ipping f i l m after incubation in 150 pmol/1 [3H]-(-)-QNB in 
the absence (A) and presence (B) of 0.1 μπιοΐ/ΐ (-)-QNB, and exposed 
for 5 months. Scale bar 11 μιπ. 
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DISCUSSION 
Binding of [ 3 H ] - ( - ) - Q N B to fixed human and bovine bronchial tissue sections 
was saturable and of high a f f i n i t y . Muscarinic receptors were localized in 
labelled tissue sections by dipping in photographic emulsion and by covering 
with str ipping f i l m . Both procedures were val id and of real value to visual ize 
muscarinic receptors in airways. The emulsion-coated covers!ip method might 
have fa i led to local ize the small receptor populations in human airways. 
Dipped human t issue sections suffered from damaged morphology. Apparently, 
f i xa t ion of human bronchial tissue sections in 0.5% glutaraldehyde for 30 min 
is insuf f ic ient to preserve intact morphology during dipping and subsequent 
exposure. A high muscarinic receptor density was found in bovine bronchial 
musculature which is in agreement with [ 3 H ] - ( - ) - Q N B binding studies with 
bovine tracheal smooth muscle membranes (chapter 5; Van Koppen et a l . 1984). 
A less dense label l ing of parasympathetic ganglia and nerves was observed. 
Although i t is generally believed that submucosal glands are chol inerg ica l ly 
innervated and the receptors involved are muscarinic, our resul ts indicate the 
contrary in th is species. In submucosal glands specif ic label l ing was absent 
and innervating cholinesterase-posit ive nerve f ibres were not observed. The 
la t te r f inding was already made by Mann (1971). 
In human bronchial t issue sections specific [3H]-(-)-QNB binding displayed a 
discrete d i s t r i bu t i on . Muscarinic receptors were found in submucosal glands, 
parasynpathetic ganglia, smooth muscle ce l l s and in nerves whereas epithelium 
and subchondrially located blood vessels were devoid of specific labe l l i ng . 
The autoradiographic findings are in agreement with the histochemical 
studies:cholinesterase-posit ive f ibres were found to innervate bronchial 
smooth muscle and submucosal glands with no evidence of innervation of blood 
vessels and epithelium. Similar results have been described by Partanen et a l . 
(1982). 
In both species muscarinic receptors appeared to be present in nerves and 
ganglia. These receptors may represent i n t race l l u l a r l y located receptors being 
transported from the nerve ce l l body to the synaptic membrane or vice versa. 
A l ternat ive ly , they may be funct ional ly active already. I t is l i k e l y that they 
are involved in the modulation of neurotransmission in one way or another. 
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Recent reports in guinea pig (Fryer and Maclagan 1984) and cat (Blaber et a l . 
1985) indicate that muscarinic receptors are present in parasympathetic nerves 
and inh ib i t airway smooth muscle contraction. 
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CHAPTER 5 
SIMULTANEOUS ASSAY OF MUSCARINIC AND ß-ADRENERGIC RECEPTORS USING 
A DOUBLE ISOTOPE TECHNIQUE 
Chris J. van Koppen, Helene L.M. Siero, Jaap F. Rodrigues de Miranda, 
Arie J. Beid and Everardus J. Ariëns 
Department of Pharmacology, University of Nijmegen 
SINMARY 
Muscarinic and ß-adrenergic receptor binding were measured simultaneously in a 
membrane f ract ion of bovine tracheal smooth muscle using [^H] - ( - ) -
quinucl idinyl benzilate ([3H]-(-)-QNB) and [1 2 5 I ]-(-)-cyanopindolol 
( [ 1 2 5 j ] . ( _ ) . C Y P ) . The binding character is t ics ; a f f i n i t y and receptor 
density, obtained in the double receptor assay and in the control experiments 
were the same within experimental error. There was no s ign i f icant influence of 
an excess of (±)-propranolol on [ 3 H ] - ( - ) - Q N B binding or a s ign i f icant 
influence of an excess of (-)-quinucl id iny l benzilate on [ 1 2 5 ι ] _ ( . ) . ς γ ρ 
binding. The method is advantageous when both receptors have to be measured 
and only l imited amounts of b io logical mater ia l , l i k e in biopsy specimen, are 
avai lable. 
INTRODUCTION 
The a v a i l a b i l i t y of t r i t i u m and iodine-125 labeled receptor l igands, which can 
be counted d i f f e r e n t i a l l y , provides the p o s s i b i l i t y of simultaneous 
determination of two types of receptors in one sample. Such a double receptor 
assay has been developed recently for measuring estrogen and progesterone 
receptors in human breast tumor cytosol ( 1 ) . We here report the simultaneous 
determination of muscarinic and ß-adrenergic receptors in bovine tracheal 
smooth muscle. Tlie presence of these receptors in th is tissue has been 
demonstrated before (2, 3 ) . 
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MATERIALS AND METHODS 
[ 3 H ] . { . ) - Q N B (123 χ 10ІО Bq/mmol) and [ 1 2 5 I ] . ( . ) . C Y P (81 χ 10І2 
Bq/mmol) were purchased from NEN-Europe. (±)-Propranolol hydrochloride was 
obtained from Sigma Chemical Co., St. Louis, USA. (-)-QNB was a g i f t from Dr. 
G. Lambrecht, Johann Wolfgang Goethe-Universität, Frankfurt/M, West Germany. 
Other reagents were of the highest qual i ty available commercially. 
Bovine tracheal smooth muscle was prepared and homogenized with carborundum as 
described previously (2). The resul t ing 100,000 g membrane pellets were stored 
at -20 0C and resuspended before use in Krebs-Henseleit buffer to give a f ina l 
t issue concentration of about 20 mg or ig inal wet weight/ml (0.2 mg 
protein/ml) . The method used for the assay of par t i c le bound receptor was the 
rapid centr i fugat ion method as described previously (4) , except that the 
samples were incubated during 90 minutes at З^С. At the end of the 
centr i fugat ion step 0.5 ml supernatant was taken for measuring free 
concentration of radioactive l igand. Then, the remaining supernatant was 
removed by suction and the t i p s of the centr i fugat ion tubes were cut o f f for 
measuring bound concentration of radioactive ligand in the p e l l e t . In the 
single [ 3 H ] - ( - ) - Q N B assay 0.5 ml of supernatant was mixed with 10 ml 
Instagel (Packard). The pel lets were dissolved in 1 ml Soluene -100 (Packard) 
and mixed with 15 ml of Instagel/1 N HCL (9:1). The samples were counted in 
the t r i t i u m channel of a Packard Tricarb 460 l iqu id s c i n t i l l a t i o n counter 
(LSC). In the single [ 1 2 5 I ]-(-)-CYP assay r a d i o a c t i v i t i e s in 0.5 ml of 
supernatant and in the p e l l e t were counted d i r e c t l y in a Nuclear Enterprises 
1612 γ-counter. In the double receptor assay supernatants and pel lets were 
f i r s t counted in the γ-counter, then s c i n t i l l a t i o n cocktai l was added as 
described for the single [ 3 H ] _ ( - ) - Q N B assay, followed by counting in the 
t r i t i u m channel of the LSC. Protein concentrations were determined by the 
method of Lowry as modified by Peterson (5) using bovine serum albumin as 
standard. The experimental data were analyzed and binding parameters 
calculated by employing a general non-linear least-squares curve f i t t i n g 
routine using the Gauss-Newton algorithm ( 6 ) . 
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RESULTS AND DISCUSSION 
Detection of iodine-125 can be performed by γ-counting (35.5 KeV γ-ray and 
27.5 KeV X-ray) with a 78% ef f ic iency and by l i q u i d s c i n t i l l a t i o n counting 
(conversion and Auger electrons at 12 and 40 KeV and 3,5 KeV X-rays) with an 
ef f ic iency of 76% in an unquenched emulsif ier s c i n t i l l a t o r solution (7) . 
D i f ferent ia l counting of t r i t i u m and iodine-125 In one sample can be achieved 
by l i q u i d s c i n t i l l a t i o n counting in two spectrum regions as recommended in the 
Packard 460C instruct ion manual (8) . As both isotopes contribute to counts 
accumulated in the t r i t i m i spectrum region, (Fig. 1) under certain 
circumstances ( i . e . i f large iodine-125/trit ium count rate rat ios are 
involved) r e l a t i v e l y large errors in the t r i t i u m count rates w i l l occur. This 
can be avoided by measuring iodine-125 in a γ-counter f i r s t . With the counting 
ef f ic iencies of iodine-125 in the γ-counter and in the t r i t i u m channel of the 
LSC known, the contr ibut ion of iodine-125 to the count rate in the t r i t i u m 
channel of the LSC can be calculated. T r i t i m i count rate follows from 
subtracting the contr ibut ion of iodine-125 from t o t a l count rate in the 
t r i t i u m channel. The r e l i a b i l i t y of the method has been tested by correlat ing 
t r i t i u m count rates in the absence and in the presence of a sevenfold excess 
of iodine-125 count rates in LSC (y = 1.02 χ + 2.9; r = 0.9999;n = 9 ) . 
rei; 
'8-
16-
14-
12-
0-
8-
6 · 
Δ-
2-
О S IO 15 20 25 30 35 40 Ab KeV 
Figure 1: Unquenched LSC-spectra of [Зн] and [ 1 2 5 l ] . Relative counts 
represent the percentage of t o t a l counts measured in the whole 
spectrum region. 
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Figure 2a: t o t a l (-) and non-specific (--) binding of [ 3 H ] - ( - ) - Q N B to bovine 
tracheal smooth muscle in the single (x) and double (o) assay. 
2b: t o t a l (-) and non-specific (--) binding of [ 1 2 5 I ]-(-)CYP to 
bovine tracheal smooth muscle in the single (x) and double (o) 
assay. 
To avoid too high count rate rat ios in the double receptor assay the 
[3H]-(-)-QNB concentration was increased paral le l with the [125i ]-(-)-CYP 
concentration. In a set of three experiments with the same tissue homogenate, 
the concentration dependent binding of [3H]-(-)-QNB alone, of 
[ 1 2 5 I ] _ ( _ ) _ C Y P alone and of [ 3 H ] - ( - ) - Q N B + [125i ]_(-)-CYP combined, was 
measured. Non-specific binding of [3H]-(-)-qNB and [125i]-(-)-CYP in the 
single experiments was determined in the presence of 0.1 μΜ (-)-QNB or 1.0 μΜ 
(±)-propranolol respectively. In the combined experiments, non-specific 
binding of [3H]-(-)-QNB and [ 1 2 5 ι ] . ( . ) . ς γ ρ
 Was determined simultaneously 
in the presence of 0.1 μΜ (-)-qNB + 1.0 μΜ (±)-propranolol. The results of 
these experiments are given in Figure 2. No s igni f icant influence of 
[ 1 2 5 I ] - ( - ) - C Y P on [ 3 H ] - ( - ) Q N B binding and vice versa could be discerned. 
The binding parameters of these experiments are summarized in table 1 
(section A). 
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Table 1: Binding parameters of [3H]-(-)-QNB and [125i].(-).ςγρ in bovine 
tracheal smooth muscle 
Type of experiment KQ (ΠΜ) RT(pmol/g) SY(ml/g) 
A. 
[3H]-(-)-QNB (single receptor assay) 
[ 3 H ] - ( - ) - Q N B (double receptor assay) 
[ 1 2 5 l ] -(-)-CYP (single receptor assay) 
[ 1 2 5 I ] . ( _ ) _ C Y P (double receptor assay) 
0.055 (6%) 
0.063 (7%) 
0.0026 (6%) 
0.0025 {8%) 
17.3 (3%) 
18.0 (4%) 
1.7 (4%) 
1.8 (6%) 
1.5 
1.4 
10.2 
10.9 
[ 3 H ] . ( . ) _ Q N B 0.058 (8%) 16.7 (4%) 1.2 
[3H]-(-)-QNB + 1.0 μΜ(±)-ρΓορΓ3ηο1ο1 0.057 (5%) 16.9 (3%) 1.2 
[125i]_(_)_cYP 
[ 1 2 5 I ] _ ( _ ) _ C Y P + 0 . 1 μΜ (-)-QNB 
0.0028· (5%) 1.4 (3%) 9.4 
0.0021 (6%) 1.4 (4%) 9.9 
Kp i s the dissociat ion constant in nM, Rj is the binding capacity in 
pmol/g or ig inal wet weight t issue. Sy is the c o e f f i c i e n t for non-specific 
binding i . e . by mult ip ly ing i t s value with the free concentration of ligand in 
nM, the non-specific binding in pmol/g or ig inal wet weight tissue at that 
concentration is obtained. Values between parentheses indicate the r e l a t i v e 
standard errors. The sets of experiments indicated with А, В and С were 
performed with d i f f e r e n t tissue homogenates. 1 g or ig ina l wet t issue 
corresponds with 10 mg protein in the f i n a l homogenates. 
In a second set of experiments carried out with another membrane suspension, 
t o t a l and non-specific concentration-dependent binding of [ 3 H ] - ( - ) - Q N B in 
the absence and presence of an excess of 1.0 μΜ (±)-propranolol was measured 
and in an analogous way t o t a l and non-specific binding of [ 1 2 5 I ] . ( . ) _ C Y P in 
the absence and presence of an excess of 0.1 μΜ (-)-QNB was determined. The 
binding parameters of these experiments are summarized in table 1 (section В 
and C). No s ign i f icant influence of an excess of (±)-propranolol on 
[ 3 H ] - ( - ) - Q N B binding or of H-QNB on [125i ]-(-)_CYP binding was found. 
A simultaneous assay of muscarinic and ß-adrenergic receptors in one sample is 
thus feasible without complications. The double receptor assay may equally 
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well be applied to the assay of any pair of receptors when d i f f e r e n t i a l l y 
labeled antagonists are avai lable, i .e . a j - and ß-adrenergic receptors using 
[3H]-prazosin as cq-selective ligand and [1 2 5 I ]-(-)-CYP as ß-adrenergic 
l igand; muscarinic and ai-adrenergic receptors using [3H]-(-)-QNB and 
[125i]_2[ß-(4-hydroxy-3-iodophenyl)ethyl aminomethyl ] tet ra lone. 
In case receptor density and a f f i n i t y rat ios are unfavourable, the specif ic 
ac t i v i t y of one of the radioligands may be lowered by d i lu t ing with unlabeled 
ligand to optimalize the count rate ra t io of iodine-125 and t r i t i um in the 
sanple. 
We are current ly involved in measuring muscarinic and ß-adrenergic receptors 
in bronchial t issue from patients with chronic obstructive lung disease. Such 
studies are often hampered by l imited mounts of tissue and with th is double 
receptor assay tissue can be saved. 
In addit ion, the double receptor assay might especial ly be advantageous to 
study a functional interact ion between d i f ferent types of receptors. 
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IN ASTtMA, CHRONIC OBSTRUCTIVE BRONCHITIS AND EMPHYSEMA 
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Jaap F. Rodrigues de Miranda, Arie J. Beid, Cees L.A. van Herwaarden^ 
and Cees A.M. van Ginneken 
Departments of Pharmacology and Pulmonary Diseases^, University of Nijmegen 
SUMARY 
The hypothesis of an increased muscarinic receptor s e n s i t i v i t y in airway 
musculature of patients with obstructive lung disease was investigated by 
receptor binding studies and contraction experiments. Receptor character ist ics 
were determined in tracheal smooth muscle of 1 patient with a l lerg ic asthma, 8 
patients with chronic obstructive bronchit is (COB), 3 patients with emphysema 
as well as in segmental bronchial t issue of 17 patients with COB, and compared 
to control values obtained in airway tissue of 49 control subjects. 
Neither receptor binding studies nor contraction experiments provided evidence 
in favour of the hypothesis. Muscarinic receptors in the tracheal smooth 
muscle preparations of the patients were present in normal density, showing 
normal antagonist binding a f f i n i t y and agonist binding character is t ics. 
Contraction studies also revealed normal receptor s e n s i t i v i t y . In segmental 
bronchial tissue of patients with COB also normal receptor numbers and 
contraction data were found. Morphometric examination of the l a t t e r 
preparations revealed normal amounts of smooth muscle and submucosal glands. 
This suggests that the excessive mucus production in COB is not accompanied by 
an increased muscarinic receptor density in submucosal glands. 
Segmental bronchial s t r ips were about 10-fold less sensitive to methacholine 
than tracheal smooth muscle str ips indicating a decline in s e n s i t i v i t y to 
muscarinic agonists along the tracheobronchial t r e e . 
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INTRODUCTION 
Airway hyperreactivity to nonspecific stimuli is a characteristic feature of 
asthma and is also frequently encountered in patients with chronic obstructive 
bronchitis (1,2). Various mechanisms have been suggested to underly airway 
hyperreactivity including enhanced epithelial permeability (3), the presence 
of inflammatory cells releasing contractile substances (4) or changes in the 
intrinsic properties of airway smooth muscle itself (5). 
A defective parasympathetic regulation may also contribute to airway 
hyperreactivity: enhanced parasympathetic influence will account for 
bronchospasm and explain the excessive mucus production by the submucosal 
glands in patients with chronic obstructive bronchitis. The defect may be 
located anywhere in the afferent and efferent vagal nerves or in their central 
nervous projections but may also be due to increased muscarinic receptor 
density or more effective receptor-effector coupling. 
The present study describes characteristics of muscarinic receptors in the 
central airway musculature of patients with asthma, chronic obstructive 
bronchitis and emphysema. The receptor density was measured by binding of the 
muscarinic radioligand [3H]-(-)-quinucl idinyl benzilate ([3H]-(-)-QNB) . 
Aspects of receptor-effector coupling were investigated by muscarinic agonist-
[3H]-(-)-QNB competition studies and by in vitro contraction experiments. 
PATIENTS AND METHODS 
Patients 
Tracheal tissue (Autopsy) 
Tracheal specimen were obtained 2-24 hours postmortemly from 30 control 
subjects without lung disease (mean age 59 ± 25 yr [SE]) and from 12 patients 
with severe obstructive lung disease. Three patients had emphysema without 
complaints of sputum expectorations, 8 patients had chronic obstructive 
bronchitis (COB) with histological evidence for emphysema and 1 patient had 
extrinsic asthma (Table 1). Diagnoses were made in accordance with the 
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standards of the American Thoracic Society (1) and based on clinical history 
and histological examination of the lung. Of 3 patients with COB (aged 64, 75 
and 80 years) lung function indices are unknown but they had severe complaints 
pointing at COB. The response of salbutamol on FEVi ("forced expiratory 
volume in 1 second") as a percentage of initial FEVi in the 5 other patients 
with COB was less than 10%. The patients did not receive anticholinergic 
therapy but most of them had been treated with bronchodilators (theophylline, 
salbutamol) and prednisolone one week before death. 
The asthmatic patient who died from end-stage Hodgkin's disease had several 
positive skintests for inhalation allergens. Salbutamol and other 
bronchodilators were not used at least 3 weeks before his decease. 
Prednisolone therapy was reduced gradually and stopped 8 days before death. 
Bronchial tissue (Operation and Autopsy) 
Bronchial tissue was obtained from 19 control subjects and 22 patients with 
mild COB undergoing lung surgery for resection of bronchial carcinoma. Lung 
function indices and reversibility of airway obstruction were assessed 
preoperatively by lung function tests (Table 1). Muscarinic receptor 
characteristics were investigated by radioligand binding and contraction 
experiments. Because the amount of tissue was too small to do both types of 
experiments, receptor binding characteristics and mechanical response data 
were assessed in tissue samples of different origin (group А, В or C). 
Improval of FEVj with 15% or more after salbutamol inhalation was observed 
only in some patients (1 in group A, 2 in group В and 1 in group C). None of 
the patients had anticholinergic therapy. Before and during operation, 
subjects received diazepam, cefuroxime, héparine, fentanyl, droperidol, 
pancuronium, suxamethonium, gallamine, isoflurane, nicomorphine, bupivacaine, 
(N2O/O2), and in most cases also atropine was given. To investigate the 
effects of these drugs on muscarinic receptor characteristics, we studied 
contraction properties of segmental bronchi obtained at autopsy from 4 
non-treated control subjects. 
About one half of the patients with COB received also theophylline, 
prednisolone and/or salbutamol to improve lung function preoperatively. 
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Table 1: Patient Characteristics3 
Source Diagnosis Age Lung function indices^ 
TLC VC FEVi FEVi/VC AFEViC(X) 
with 
(X) (%) (%) % salbutamol 
Autopsy 
tracheal 
smooth muscle 
Operation 
Group A 
main bronchia 
smooth muscle 
(receptor 
binding) 
Group В 
segmental 
bronchial 
t issue 
(receptor 
binding) 
Group С 
segmental 
bronchial 
t issue 
(contraction) 
Asthma 
COB 
(n=8)d 
Emphysema 
(n-3) 
Controls 
1 (n-Z) 
COB 
(n-5) 
Controls 
(n-10) 
COB 
(n-10) 
Controls 
(n-7) 
COB 
(n-7) 
39 
67+13 
(n-5) 
42 
61 
69 
44 
58 
59±6 
56±15 
61±13 
70+9 
70+7 
5.8 
(95) 
6.0±1.1 
(97+16) 
6.1 
(122) 
6.7 
(in) 
8.1 
(136) 
3.8 
(78) 
5.4 
(100) 
5.8+1.6 
(85±22) 
6.1+1.3 
(96+17) 
6.2±0.9 
(100+16) 
6.7+1.8 
(100±19) 
5.6+1.3 
(86±12) 
3.3 
(77) 
3.2±0.7 
(82±14) 
4.2 
(117) 
2.8 
(73) 
3.1 
(82) 
2.7 
(84) 
3.5 
(112) 
3.3+0.8 
(78+20) 
4.0±0.7 
(105+13) 
3.4±0.4 
(90±12) 
4.0±1.0 
(103±13) 
2.9+1.2 
(79±18) 
1.2 
(34) 
1.2+0.4 
(46±10) 
1.6 
(63) 
1.5 
(60) 
0.6 
(24) 
2.3 
(88) 
2.5 
(100) 
1.9±0.5 
(59+18) 
2.9+0.5 
(96+11) 
2.0±0.3 
(70+11) 
2.6±0.7 
(93±15) 
1.7+0.5 
(61+15) 
38 
39 + 8 
39 
55 
20 
85 
71 
57 + 4 
7 1 + 6 
60 + 9 
6 5 + 6 
55 + 4 
24 
see 
text 
0 
12 
22 
see 
text 
see 
text 
see 
text 
Abbreviations: TLC = total lung capacity, VC = vital capacity, FEVi = forced 
expiratory volume in 1 sec (all in litres); COB = chronic obstructive 
bronchitis. a Values are mean ± SE; b Between parentheses: percentages of 
predicted normal values (25); c Increase in FEVi a s percentage of initial 
value; d From 3 patients with COB lung function indices are unknown. 
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Nethods 
Membrane preparation 
Smooth muscle from trachea and main bronchus was prepared as described in 
chapter 2 (6). The segmental bronchi were dissected out of the external lung 
parenchyma, freed from mucus plugs and cut open. A crude segmental bronchial 
tissue sample containing epithel ium, smooth muscle, submucosal glands, 
connective tissue etc. was obtained by scraping the bronchial wall with a 
scapel t i l l the surrounding cart i lage was reached. 
Tissue was homogenized and processed as described in chapter 2 (6). The 
resul t ing 100,000 g membrane pel let was stored at -80PC. 
Hjscarinlc receptor assay 
Receptor character ist ics were assessed with [ 3 H ] - ( - ) - Q N B (spec. act. 
123x1010 Bq/mmol, NEN Europe) as radiol igand. Binding experiments with 
tracheal smooth muscle membranes were performed as described in chapter 2 
(6). Receptor density in bronchial t issue was determined simultaneously with 
ß-adrenoceptor density using the double receptor assay as described in chapter 
5 (7). Incubations were done in Krebs-Ringer buffer pH 7.0 at 370C for 90 min 
and terminated by с e n t r i fug at ion at 18,000 g for 15 min. In saturation binding 
experiments, the [ 3 H ] - ( - ) - Q N B concentration ranged from 5 to 1250 pmol/1. 
Competition experiments with methyl furtrethonium (synthesized in our 
laboratory) were performed at a fixed [ 3 H ] - ( - ) - Q N B concentration between 160 
and 250 pmol/1 and in the presence of 100 μηοΐ/ΐ phenylmethylsulfonylfluoride 
(Sigma) as protease i n h i b i t o r . Specific [ 3 H ] - ( - ) - Q N B binding was defined as 
the difference between binding in the absence and presence of 0.1 цлюі/і 
unlabelled (-)-QNB ( g i f t from Dr. G. Lambrecht, Frankfurt/Main). Binding 
parameters were calculated by a non-linear least-squares curve f i t t i n g 
rout ine. As a f f i n i t y values are log normally d istr ibuted ( 8 ) , рКр-, рКц-
and рК|_- а1ие5 are given. Protein concentrations were measured according to 
Peterson (9) using bovine serum albumin as standard. 
Contraction studies 
Tracheal smooth muscle st r ips and s p i r a l l y cut segmental bronchial str ips (10) 
were contracted i s o t o n i c a l l y with methacholine (Sigma) under a load of 0.5 g 
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in Krebs-Henseleit buffer pH 7.4 (ЗТ^С), supplemented with 5 mmol/1 glucose 
and aerated with 5% C02/95% O2. Cumulative dose-contraction curves were 
made; pDj-values and H i l l - c o e f f i c i e n t s (пн) were calculated as described 
in chapter 2 (6). The pDj-value is the negative logarithm of the 
concentration (mol/1) producing halfmaximal contract ion, and the пц value 
represents the slope of the H i l l plot and is a quantitat ive measure for the 
steepness of the log dose-contraction curve. 
Histology 
Specimen of the segmental bronchi were f ixed in 2.5% g lutar aldehyde in 0.1 
mol/1 phosphate buffer pH 7.0 , dehydrated in ethanol and embedded in 
glycolmethacrylate (JB4 embedding k i t , Polysciences Inc. Warrington PA, USA). 
Sections were stained with Toluidine Blue (2%). The r e l a t i v e proportions of 
submucosal glands and smooth muscle as percentage of t o t a l bronchial area were 
determined according to Restrepo and Heard (11). 
Statistical analysis 
Al l methylfurtrethonium i n h i b i t i o n curves were f i t t e d to a one- or two-site 
model. Goodness of f i t was compared by the F-test. Differences in " a f f i n i t y " 
values (рК^; рКц and рК|_; pD2) and percentages of receptors in the 
high a f f i n i t y state (SÍRH) which are known to be normally distr ibuted (8,12) 
were compared using the Student's t t es t . Differences in receptor densit ies 
( R T ) I пн-values and areas of smooth muscle and submucosal glands were 
compared by the Wilcoxon rank sum t e s t . Significance was accepted at Ρ < 0.05. 
RESULTS 
1. Muscarinic receptor characteristics in snooth muscle of trachea and aain 
bronchus 
A. Antagonist and agonist binding 
Figure 1 shows a curve of concentration-dependent [3H]-(-)-QNB binding to 
tracheal smooth muscle membranes of a patient with COB. Specific 
[^H]-(-)-QNB binding was saturable and of high affinity. 
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Fig. 1: Concentration dependent binding of [ 3 H ] - ( - ) - Q N B to tracheal 
smooth muscle membranes of a patient with chronic obstructive 
bronchi t is . Insert : Scatchard plot of the specif ic [ 3 H ] - ( - ) - Q N B 
binding. 
[ 3 H ] - ( - ) - Q N B binding parameters were not dependent on location in the 
trachea or main bronchus. Figure 2 summarizes the [3H]-(-)-QNB binding 
parameters determined in tracheal and main bronchial smooth muscle membranes 
of controls and pat ients. All patients showed normal antagonist 
( [ 3 H ] - ( - ) - Q N B ) binding parameters (pK^ and Rj values) although the 
asthmatic patient had a very low muscarinic receptor density. 
In contrast to muscarinic antagonists l i k e [ 3 H ] - ( - ) - Q N B and atropine, 
muscarinic agonists discriminate between high and low a f f i n i t y binding s i t e s . 
I t is s t i l l a subject of study whether or not these binding sites are 
d i f f e r e n t i a l l y coupled to certain muscarinic receptor-mediated responses l i k e 
the stimulation of phosphatidyl inos i to l turnover, transmembranal ion transport 
and i n h i b i t i o n of adenylate cyclase (13, and references herein). 
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Fig. 2: [3H]-(-)-QNB binding parameters in smooth muscle membranes of 
trachea and main bronchus. Individual values of the negative 
logarithm of affinity constants (pK^) and receptor density (Rj) 
are given. The mean ± SEM is given at the bottom of each colunn. 
Horizontal bars indicate mean values. Binding parameters of patients 
with chronic obstructive bronchitis (COB) and emphysema did not 
differ significantly from controls. 
To investigate a possible relationship between agonist binding and lung 
function, we studied the inhibition of [3H]-(-)-QNB binding by the 
muscarinic agonist methylfurtrethonium. Methylfurtrethoniim inhibition curves 
could be analyzed adequately by a two binding site model. The relative 
proportions of high and low affinity agonist binding sites as well as their 
рКн and рК|_ values did not deviate from controls. (Table 2; Fig.3). 
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Fig. 3: 
Fractional inhibition of 
specific [3H]-(-)QNB binding 
by methyifurtrethonium to 
tracheal smooth muscle membranes 
of the asthmatic patient. The 
curve was fitted by a two 
binding site model. The negative 
logarithm of the affinity 
constants of the high (рКн) 
and low (рК|_) affinity binding 
sites, and the relative 
proportion of high affinity 
sites (%RH) are given. 
Table 2: Methyifurtrethonium binding parameters in tracheal smooth muscle 
membranes. 
РКн 
pKL «RH 
Controls 5.51 
5.80 
6.22 
4.22 
4.72 
4.82 
81 
38 
58 
Asthma 5.57 4.75 42 
СОВа 
Emphysema 
5.52 
5.82 
5.89 
6.00 
6.22 
4.52 
4.46 
4.29 
4.72 
4.82 
40 
34 
72 
46 
23 
Methyifurtrethonium binding parameters were determined in 
[3H]-(-)-QNB competition experiments in tracheal smooth muscle 
membranes. All inhibition curves could be fitted adequately by a 
model of two classes of binding sites, RH and RL with 
corresponding affinity constants Кц and KL given in the table as 
negative logarithm values. The relative proportions of high affinity 
sites are given as percentage of specific binding (%RH). Binding 
characteristics of patients with COB and emphysema did not differ 
significantly from controls. aCOB: chronic obstructive bronchitis. 
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В. Contraction studies 
Tracheal smooth muscle str ips were contracted with increasing doses of 
methacholine. Methacholine was used instead of methylfurtrethonium because 
reversal of methyl furtrethoni im- induced contraction was extremely slow 
compared to methacholine. As shown in Figure 4, smooth muscle s t r i p s of 
patients with COB, emphysema and asthma had pDj- and пн-values comparable 
to those found in controls. 
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(N=1) 
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(N=5) 
EMPHYSEMA |N=2) 
Fig. 4: Methacholine-induced contraction parameters in tracheal smooth 
muscle. Individual pD2-values and H i l l coeff ic ients (ημ) are 
given. The mean ± SEM is given at the bottom of each column. 
Horizontal bars indicate mean values. Data of the asthmatic patient 
are the mean ± SEM of 3 dose-contraction curves. Contraction data from 
patients with chronic obstructive bronchit is (COB) and emphysema did 
not d i f f e r s i g n i f i c a n t l y from controls. 
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Ζ. Muscarinic receptor characteristics in segmental bronchial tissue 
A. Antagonist binding 
[ 3 H ] - ( - ) - Q N B binding parameters were determined in segmental bronchial 
t issue membranes of 10 control subjects and 10 patients with COB (Group B, 
Table 1 ) . To account for possible submucosal oedema, receptor densities were 
expressed in pmol/g tissue as well as in fmol/mg protein (Fig. 5) . Both 
expressions of receptor density and pKg-values were of equal magnitude in 
controls and COB. From a l imited number of subjects; 3 controls and 3 patients 
with COB, lobar bronchial t issue was received. In these preparations higher 
muscarinic receptor densities were found: Rj of 1.23 ± 0.27 pmol/g in 
controls and 1.08 + 0.43 pmol/g in COB (mean ± SEM). 
1025-
«τ (Ρ 
1 2 5 -
1 0 0 -
0 7 5 -
0 5 0 -
0 2 5 -
mol/g tissue) 
• 
1 
• 
• 
0601007 
о 
о 
о 
1-
о 
0 
0 
0 6 5 * 0 0 9 
125-
100-
75 
50-
25-
è 
• 
• 
• 
• 
• 
ι 
5¿±8 
о 
о 
о 
О 
- о -
о 
о 
о 
о 
о 
6U11 
Fig. 5: [3H]-(-)-QNB binding parameters in segmental bronchial tissue 
membranes of control subjects (·) and patients with chronic 
obstructive bronchitis (o). Muscarinic receptor densities (Rj) are 
expressed in pmol/g wet weight tissue and in fmol/mg protein. 
Individual values are given. The mean ± SEM is given at the bottom of 
each column. Horizontal bars indicate mean values. Binding 
characteristics of patients with chronic obstructive bronchitis (COB) 
differed not significantly from controls. 
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Hyperplasia and hypertrophy of submucosal glands and smooth muscle in severe 
COB have been described (11, 14, 15). As these tissues have a parasympathetic 
innervation (16), such histologic changes might o b l i t e r a t e deviating receptor 
numbers. We therefore estimated the re lat ive proportions of these tissue types 
by measuring the i r areas in histologic sections of the bronchial t issue 
samples. Snooth muscle and submucosal gland areas in the pat ient 's segmental 
bronchi did not appear to be s i g n i f i c a n t l y d i f f e r e n t from controls: (7.0 ± 
0.6)% and (11.7 ± 1.2)% versus (9.0 ± 2.0)% and (11.8 ± 1.6)% in controls 
(mean ± SEM). 
В. Contraction studies 
Segmental bronchial s t r i p s of 7 control subjects and 7 patients with COB 
(Group C, Table 1) had similar methacholine pD2- and пн-values (Fig. 6) . 
Remarkably, bronchial pD2-values were about one log unit smaller than 
tracheal p02-values (see Fig. 4) . The difference is most probably not caused 
by the drugs administered before and during operation because similar 
pD2-values were found in segmental bronchial str ips received at autopsy from 
nontreated normal individuals (Fig. 6 ) . 
p D 2 -
6 0 
5 0 -
: : 5 9 ¿ Í 0 0 ¿ i 5771015 i 595i 016 
CONTROLS COB CONTROLS 
(N = 7) |N = 7] |N = i) 
operation operation autopsy 
Fig. 6: 
Methacholine-induced contraction para-
meters in segmental bronchi. Individual 
parameters are given with the mean ± 
SEM at the bottom of each column. 
Horizontal bars indicate the mean 
values. 
Contraction data did not differ 
significantly between groups. COB = 
chronic obstructive bronchitis. 
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DISCUSSION 
One of the mechanisms underlying obstructive lung disease might be an 
increased muscarinic receptor sensitivity in airway musculature. 
We investigated muscarinic receptor characteristics in central airway smooth 
muscle of patients with obstructive lung disease. Neither receptor binding nor 
contraction experiments however provided evidence in favour of this 
hypothesis. Muscarinic receptors in the tracheal smooth muscle preparations 
were present in normal density, showing normal antagonist binding affinity and 
agonist binding characteristics. 
Contraction studies with tracheal smooth muscle strips also revealed normal 
muscarinic receptor sensitivity. These findings are probably not confined to 
tracheal smooth muscle: segmental bronchial strips also showed normal 
methacholine sensitivity in patients with COB. Also [3H]-(-)-QNB binding to 
segmental bronchial tissue membranes appeared to be normal. However, these 
data must be interpreted with caution because muscarinic receptors in 
bronchial tissue are also located in submucosal glands (see Chapter 4 ) . As 
total submucosal gland and smooth muscle areas were unchanged in COB, it is 
tempting to speculate that the excessive mucus production in COB is not 
accompanied with an increased muscarinic receptor density in submucosal 
glands. In lobar bronchi higher receptor densities were found. A regional 
variation in submucosal gland population may be responsible for the difference 
as the gland area appears to decline along the hunan bronchial tree (17). 
Our findings, although a limited nunber of patients was studied, confirm 
recent contraction studies (18, 19, 20) reporting unaltered muscarinic 
receptor sensitivity in airway smooth muscle strips from asthmatics and 
patients with airway hyperreactivity. 
As airway obstruction in emphysema is a consequence of reduced elastic recoil 
through extensive destruction of the alveolar walls, there is no reason a 
priori to assume that muscarinic receptor function in central airway smooth 
muscle of patients with emphysema is altered. 
In peripheral lung homogenates of patients with COB increased muscarinic 
receptor numbers have been reported (21). Our findings indicate that the 
deviating receptor numbers in lung tissue of patients with COB are not caused 
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by alterat ions in segmental bronchi. Receptor populations in the smaller 
airways, nerve f ibres or blood vessels may be al tered. 
The segmental bronchial s t r ips showed an almost 10-fold lower s e n s i t i v i t y for 
methacholine than tracheal smooth muscle s t r i p s . The presence of airway 
epithelium in the bronchial s t r ips can only p a r t l y be responsible for the 
discrepancy as removal of epithelium increases the s e n s i t i v i t y of human 
tracheal smooth muscle to methacholine only 2-fold (22). A reason for worry 
could be the presence of the cholinergic drugs atropine and gal lamine which 
the patients received before and during operation respectively. Both compounds 
w i l l have saturated muscarinic receptors to a certain extent at t issue 
rece ipt . This binding w i l l not interfere with [ 3 H ] - ( - ) - Q N B binding as both 
drugs dissociate r e l a t i v e l y fast and d i l u t i o n in the organ bath w i l l reduce 
re-association to a negl ig ible level (23, 24). However, they could have 
induced muscarinic receptor changes during operation. We determined 
methacholine s e n s i t i v i t y in segmental bronchial s t r i p s received postmortemly 
from nontreated subjects. As shown in Figure 6 pD2-values and H i l l 
coef f ic ients corresponded well with those observed in bronchial s t r ips 
received post-operatively. These functional data indicate that human airway 
musculature does not respond to inhaled muscarinic agonists with equal 
s e n s i t i v i t y along the tracheobronchial t r e e . 
In summary, the in v i t r o studies do not provide evidence in favour of an 
altered muscarinic receptor function in airway musculature and suggest that 
other mechanisms are involved in airway obstruct ion. 
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β-ADRENOCEPTOR BINDING AND INDUCED RELAXATION IN CENTRAL AIRWAY SMOOTH 
MUSCLE OF PATIENTS WITH OBSTRUCTIVE LUNG DISEASE 
Chris J. van Koppen, Harry G. Mouris, Jaap F. Rodrigues de Miranda, 
Arie J. Beid, Cees L.A. van Herwaarden^, Jan Willem J. Lammersl 
and Cees A.M. van Ginneken 
Departments of Pharmacology and Pulmonary Diseases^, University of Nijmegen 
SUMMARY 
The hypothesis of a β-adrenoceptor dysfunction in central airway musculature 
of patients with obstructive lung disease was investigated by receptor binding 
studies and relaxation experiments. Receptor character ist ics were determined 
in tracheal smooth muscle preparations of 1 patient with a l lerg ic asthma, 9 
patients with chronic obstructive bronchit is (COB) and 3 patients with 
emphysema, and in bronchial t issue of 21 patients with COB. The characteris­
t i c s were compared to those obtained in airway tissue of 65 control subjects. 
The number of ß-adrenoceptors as well as the i r antagonist binding a f f i n i t y 
were comparable to control values. Relaxation experiments with tracheal smooth 
muscle str ips revealed diminished isoprenaline sens i t i v i t y in patients with 
COB and the asthmatic patient compared to control subjects (pD2-values of 
6.26 ± 0.20, 5.55 and 6.62 ± 0.15 respect ively). Tracheal smooth muscle str ips 
of patients with emphysema displayed normal sens i t i v i t y to isoprenaline 
(pDj-value of 6.49 ± 0.29). Segmental bronchial str ips of patients with COB 
also showed reduced isoprenaline sens i t i v i t y (pD2 value of 6.55 ± 0.27 vs 
7.14 ± 0.12 in cont ro ls) . Isoprenaline binding to tracheal smooth muscle 
membranes of patients with COB and emphysema was normal. This indicates that 
ß-adrenoceptors in airway smooth muscle of patients with COB and emphysema are 
not defective and suggests that in COB there is a less e f fec t ive coupling 
between components of the relaxant system dista l to the ß-adrenoceptor. In the 
tracheal smooth muscle of the patient with asthma isoprenaline was found to 
bind with lower a f f i n i t y to the high a f f i n i t y state of the ß-adrenoceptor. 
This suggests an impaired coupling of ß-adrenoceptors with adenylate cyclase 
in asthma. 
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INTRODUCTION 
Among the various mechanisms supposed to underly bronchial hyperreactivity in 
asthma and chronic obstructive bronchi t is , the ß-adrenoceptor theory of 
Szentivanyi (1) has received part icular at tent ion. Szentivanyi postulates that 
the basic abnormality in asthma is an inherited or acquired ß-adrenoceptor 
dysfunction decreasing the effectiveness of ß-adrenergic agonists which 
normally would produce adequate bronchodilatation. 
In the sensitized guinea pig model of asthma, reduced pulmonary ß-adrenoceptor 
densit ies (2,3,4,5) and diminished relaxation responses to ß-adrenergic 
agonists (4,6) have been found. 
The paucity of airway tissue from asthmatic patients has hampered the 
ve r i f i ca t i on of the ß-adrenoceptor theory in humans. In two of the few studies 
dealing with asthmatic airway smooth muscle decreased ß-adrenoceptor 
sens i t i v i t y has been described (7,8) . These f indings however are not en t i re l y 
convincing for a defective ß-adrenoceptor in asthma as reduced isoprenaline 
sens i t i v i t y can equally well be based on higher in t r ins ic tone or less 
e f fec t ive coupling of the ß-adrenoceptor with the relaxant system. 
Or ig ina l ly postulated as a mechanism in asthma, the ß-adrenoceptor theory has 
been considered to account for increased airway reac t i v i t y in general (9) . 
The purpose of the present study was to investigate the ß-adrenoceptor 
theory in central airway smooth muscle of patients with asthma, chronic 
obstruct ive bronchit is (COB) and emphysema. ß-Adrenoceptor character ist ics 
were determined by radioligand binding studies and in v i t ro relaxation 
experiments. The number of ß-adrenoceptors was measured by binding of the 
antagonist [ 1 2 5 l ] - ( - ) -cyanopindolo l ( [ 1 2 5 I ] - ( - ) -CYP) . The coupling of the 
ß-adrenoceptor with the relaxant system was studied by 
isoprenal ine-[125i]_(_)_(;Yp competition experiments and isoprenal ine-induced 
relaxat ion responses. We also determined the responsiveness of bronchial 
smooth muscle preparations to isoprenaline at varying levels of muscular tone 
induced by methachol ine. 
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PATIENTS AND METHODS 
Patients 
Tracheal tissue (Autopsy) 
Tracheae were obtained at autopsy within 24 hours af ter death from 44 control 
subjects (age 60 ± 20 years; postmortem delay 14 + 8 hours, mean ± SE) and 13 
patients with severe obstructive lung disease (age 64 + 14 years; postmortem 
delay 1 7 + 6 hours) (Table 1). Diagnoses of the patients were made in 
accordance with the standards of the American Thoracic Society (10) and were 
based on medical history of the patients and morphological investigation of 
the lung. Three patients had morphological evidence for emphysema and were 
free of symptoms of chronic bronchi t is , 9 patients had chronic obstructive 
bronchit is (COB) with morphological evidence for emphysema and 1 patient had 
al lergic asthma. Only some patients demonstrated par t ia l r e v e r s i b i l i t y of 
airway obstruction after inhalation of salbutamol. The patients received 
bronchodilators ( theophyl l ine, salbutamol) and prednisolone in the week 
preceding death, except one patient with COB and the asthmatic pat ient. The 
asthmatic patient who died from end-stage Hodgkin's disease had not used 
salbutamol or other bronchodilator at least during 3 weeks before his decease. 
Prednisolone medication was reduced gradually and stopped 8 days before death. 
Bronchial t issue (Operation) 
Bronchial tissue was obtained from 21 control subjects and 21 patients with 
COB undergoing thoractomy for bronchial carcinoma (Table 1) . Lung function 
indices were usually determined within one week before operation. 
ß-Adrenoceptor character ist ics were investigated by radioligand binding 
experiments (Group A and B) and relaxation studies (Group C). In group В only 
2 patients had received theophyl l ine, prednisolone or salbutamol and only 2 
patients showed an increase in FEVi ("forced expiratory volume in 1 sec") of 
more than 15% after salbutamol inhalat ion. 
95 
σ, Table 1: Patient Characteristics3 
Source 
AUTOPSY 
tracheal 
smooth muscle 
Diagnosis 
Asthma 
COB 
(n = 9) 
Emphy­
sema 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
1. 
2. 
Age 
39 
64 
69 
78 
62 
87 
85 
64 
59 
55 
69 
42 
Lung function ine 
TLC 
(*) 
5.8 (95) 
5.2 (78) 
6.9 (100) 
N.D. 
7.5 (ИЗ) 
5.2 (90) 
6.8 (112) 
5.4 (89) 
8.1 (136) 
6.1 (122) 
VC 
(*) 
3.3 
2.9 
4.6 
3.0 
3.2 
2.1 
4.0 
3.6 
3.1 
4.2 
licesb 
(77) 
(78) 
(ПО) 
(77) 
(76) 
N.D. 
(68) 
N.D. 
(100) 
(91) 
(82) 
(117) 
FEV] 
(X) 
1.2 
1.0 
1.0 
0.9 
0.9 
1.0 
1.5 
1.7 
0.6 
1.6 
(34) 
(37) 
(32) 
(34) 
(33) 
(44) 
(56) 
(63) 
(24) 
(63) 
FEVi/VC 
% 
38 
34 
22 
28 
29 
46 
38 
48 
20 
39 
AFEViC with 
salbutamol 
(%) 
24 
0 
0 
0 
8 
10 
9 
18 
22 
0 
Medication 
-
T.S 
T.P.S 
T.P.S 
T.P 
s 
T.P.S 
T.S 
T.S 
-
T.P.S 
T.P.S 
12 
OPERATION 
GROUP A 
main bronchial Control 
smooth muscle 
(receptor- COB 
binding) (n = 3) 2. 59 4.4 (69) 2.5 (63) 1.3 (43) 52 15 S 
3. 69 6.5 (98) 4.3 (100) 2.5 (86) 58 10 T.S 
61 
58 
56 
6.7 (111) 
5.4 (100) 
8.3 (117) 
2.8 (73) 
3.5 (112) 
4.0 (85) 
1.5 (60) 
2.5 (100) 
2.4 (67) 
55 
71 
60 
GROUP В 
lobar & 
segmental 
bronchial 
tissue 
(receptor-
binding) 
GROUP С 
segmental 
bronchial 
tissue 
(relaxation) 
Controls 
(n = 9) 
COB 
(n = 8) 
Controls 
(n = 11) 
COB 
(n = 10) 
58 
63 
63 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
± 17 
± 8 
± 14 
69 
57 
68 
30 
68 
75 
53 
65 
61 
60 
6.6 ± 1.3 
(107 ± 29) 
6.2 ± 0.9 
(92 ± 11) 
6.3 ± 1.8 
(97 ± 18) 
5.5 (79) 
4.6 (93) 
7.0 (93) 
3.6 (74) 
7.4 (103) 
N.D. 
8.0 (114) 
7.2 (99) 
6.7 (93) 
5.5 (77) 
4.0 ± 0.8 
(107 ± 15) 
3.6 ± 0.5 
(87 ± 10) 
4.1 ± 0.9 
(105 ± 17) 
3.0 (64) 
2.0 (86) 
4.5 (105) 
2.4 (67) 
4.2 (96) 
2.4 (53) 
5.4 (119) 
3.2 (71) 
4.3 (105) 
3.5 (77) 
2.8 
(95 
2.0 
(65 
2.8 
(96 
1.6 
1.1 
2.8 
1.5 
2.0 
1.4 
3.2 
1.6 
2.4 
2.3 
± 0.5 
± η) 
± 0.3 
± 6 ) 
± 0.8 
± 15) 
(45) 
(59) 
(84) 
(50) 
(61) 
(42) 
(88) 
(47) 
(77) 
(65) 
70 ± 7 
56 + 2 
68 ± 0.07 
52 
55 
61 
60 
48 
58 
58 
50 
56 
64 
-
see 
text 
-
6 
10 
N.D. 
0 
3 
14 
7 
13 
12 
2 
-
see 
text 
-
T,S 
T,P,S 
T,S 
T.P.S 
T,P,S 
T.P.S 
-
T.P.S 
T.S 
Abbreviations: TLC = total lung capacity, VC = vital capacity, FEVi = forced expiratory volime in 
1 sec (all in litres); COB = chronic obstructive bronchitis; Τ = theophylline; 
Ρ = prednisolone; S = salbutamol; N.D. = not determined. 
aValues are mean ± SE. b B
e
t
w e e n
 parentheses: percentages of predicted normal 
value (19). cIncrease in FEV! as percentage of initial value. 
Chapter 7 
Methods 
Receptor binding experiments 
Membrane preparations of central airway t issue were made as described in 
Chapter 6. The resul t ing 100,000 g membrane pel lets were stored at -80PC. 
ρ-Adrenoceptor binding characterist ics were studied using [125i]_(_)_cYP 
(spec. act. 81 χ 10^2 Bq/mmol, NEN Europe) as radiol igand. Binding 
experiments with tracheal smooth muscle membranes were done as described in 
Chapter 3. The ß-adrenoceptor density in main bronchial smooth muscle and 
lobar-segment al bronchial tissue was determined simultaneously with the 
muscarinic receptor density using a double receptor assay as described in 
Chapter 5. For accurate determination of the muscarinic receptor density with 
[^H]-(-)-QNB, i t was necessary to reduce the specif ic ac t i v i t y of 
[ 1 2 5 I ] _ ( _ ) _ C Y P about one order of magnitude by d i lu t ion with unlabelled 
(±)-ICYP (kindly provided by Dr. G. Engel, Sandoz, Switzerland). 
Incubations were carried out in Krebs-Ringer buffer pH 7.0 at 370C for 90 min 
and terminated by centr i fugat ion at 18,000 g for 15 min or by f i l t r a t i o n 
through Whatman GF/C f i l t e r s followed by washing. In concentration-dependent 
[ 1 2 5 I ] _ ( _ ) _ C Y P binding experiments, radioligand concentrations ranged from 5 
to 50-80 pmol/1. Isoprenaline competition experiments were done with a f ixed 
[125ι]_(_)_(;γρ concentration between 5 and 14 pmol/1 in the presence of 0.1 
mmol phenyl methyl sul fony l f luor ide (Sigma) as protease inhib i tor and 1 mmol/1 
ascorbic acid (Merck) to counteract oxydation of isoprenaline. Specific 
[ 1 2 5 I ] _ ( _ ) _ C Y P binding was defined as the difference between binding in the 
absence and presence of 1.0 μπιοΐ/ΐ (±)-propranolol. Binding parameters were 
calculated by a non-linear least-squares curve f i t t i n g program (11). Protein 
concentrations were measured according to Peterson (12) with bovine serum 
albimin as standard. 
Relaxation experiments 
Tracheal smooth muscle str ips and s p i r a l l y cut bronchial str ips (13) were 
relaxed isotonica l ly with isoprenaline under a load of 0.5 g in 
Krebs-Henseleit buffer pH 7.4 (370C), supplemented with 5 mmol/1 glucose and 
aerated with 5% C02/95% Oj. After test ing the responsiveness of the str ips 
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with 10"6 mol/1 methacholine and washing, cumulative dose-response curves 
for isoprenaline were recorded in the absence and presence of 10"6 or 10"^ 
mol/1 methacholine. Preliminary experiments showed that contraction obtained 
with 10"4 mol/1 methacholine was stable for the period required to construct 
a complete relaxation curve. The recording of an isoprenaline relaxation curve 
and subsequent washing took about 3 hours. 
Tracheal smooth muscle responses were measured in two or three str ips in 
duplicate. Relaxation responses of segmental bronchial str ips were determined 
in duplicate when possible; either in the same preparation or in two d i f f e r e n t 
s t r i p s . 
The pD2-values and H i l l coeff ic ients (пн) were calculated as described in 
Chapter 2. The pDj-value is the negative logarithm of the concentration 
(mol/1) producing half maximal relaxat ion, and the пн-value represents the 
slope of the H i l l p lot and is a quanti tat ive measure for the steepness of the 
log dose-relaxation curve. Isoprenaline was dissolved in d i s t i l l e d water 
containing 6 mtiol/l ascorbic acid. 
Horphometric analysis 
Samples of the bronchi which were used for radioligand binding experiments 
(Table 1, Group B) were f ixed and embedded in glycolmethacrylate as described 
in Chapter 6. The r e l a t i v e proportions of submucosal glands and smooth muscle 
as percentage of t o t a l bronchial area were determined according to Restrepo 
and Heard (14). 
Statistical analysis 
Isoprenaline competition curves were f i t t e d to a one- or two binding s i te 
model. Preference was given to the two binding s i t e model when a s ign i f icant 
diminution in the residual sum of squares was reached ( F - t e s t ) . The Student's 
t - t e s t was used for analyzing differences in the negative logarithm of 
a f f i n i t y constants (рК^; рКц and рК|_) and percentages of receptors in 
the high a f f i n i t y state (%RH). Differences in pDj-values, H i l l 
coef f ic ients and morphometrically determined areas were compared by the 
Wilcoxon rank sum t e s t . For paired observations ( i . e . pD2-values in Figure 7 
A and B) the Student's t - t e s t was used. Significance was accepted at Ρ < 0.05. 
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RESULTS 
1. β-Adrenoceptor characteristics in snoot h muscle of trachea and main 
bronchus 
A. [ 1 2 5 I ] _ ( _ ) _ C Y P binding 
Figure 1 shows concentration-dependent [№$1 ]-(-)-CYP binding to tracheal 
smooth muscle membranes of a patient with emphysema. Analysis of the curve 
resulted in a dissociat ion constant (Kj) of 1.9 pmol/1 (pKj of 11.72) and 
a receptor density (Ry) of 170 fmol/g t issue. Specific binding was saturable 
and of high a f f i n i t y . 
["»U-
400-
300 
200 
100 
-)-CYP bound (fmol/g) 
bound/free 
C1"]]-!-)-CYP free (pmol/1) 
Fig. 1: Concentration-dependent binding of [ Ι ^ ι ] . (_) .ςγρ to tracheal smooth 
muscle membranes of a patient with emphysema, о t o t a l binding, 
Δ non-specific binding. Insert: Scatchard plot of the specif ic 
binding. 
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In Figure 2 [125i]_(_)_CYP binding parameters determined in tracheal and 
main bronchial smooth muscle membranes of control subjects and patients (Table 
1: autopsy and operation group A) are summarized. 
The concentration-dependent [125l]-(-)CYP binding experiments revealed 
receptor numbers and a f f i n i t i e s in patients which were well within the range 
of control values. 
pKd 
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ВЗііЗ 
CONTROLS ASTHMA 
(N = 33) (N = 1) 
COB EMPHYSEMA 
(N=11) (N=3) 
Fig. 2: [125I]_(_)_CYP binding parameters in tracheal and main bronchial 
smooth muscle membranes. Individual values of receptor density (Rj) 
and binding affinity expressed as the negative logarithm of the 
dissociation constant (Kj) are given. Horizontal bars Indicate mean 
values. The mean ± SEM is given at the bottom of each column. Binding 
parameters in patients with COB and emphysema were not significantly 
different from control values. COB = chronic obstructive bronchitis. 
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В. Isoprenal ine-induced relaxation and binding 
In addition to receptor binding, relaxation responses were studied (Fig. 3 ) . 
Tracheal smooth muscle of the asthmatic patient had a tenfold lower 
isoprenaline s e n s i t i v i t y . The 6 patients with COB had pOj-values comparable 
with those in the lower range of control values. This trend did not at ta in 
s t a t i s t i c a l s ignif icance. The patients with emphysema had normal values. The 
H i l l coeff ic ients in patients and control subjects were of comparable 
magnitude and close to one. 
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(N = 12) 
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COB (N = 6) EMPHYSEMA (N = 2) 
F1g. 3: Isoprenal ine-induced relaxation of tracheal smooth muscle without 
precontraction by methacholine. Individual pD2-values and H i l l 
coef f ic ients (пн) are given (the f igures refer to Table I "Autopsy") 
and horizontal bars indicate mean values. The mean ± SEM is given at 
the bottom of each column. Data of the asthmatic patient are from 4 
experiments. Relaxation parameters of patients with chronic 
obstructive bronchit is (COB) and emphysema were not s i g n i f i c a n t l y 
d i f f e r e n t from control data. 
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To investigate whether the lower pD2 values in the asthmatic patient and 
patients with COB are ref lected in deviating isoprenaline binding propert ies, 
isoprenal ine-[125i].(.)-CYP competition experiments were carried out. 
The isoprenaline competition curve of the asthmatic patient is given in 
Figure 4. Isoprenal ine's рКн-value of 7.40 was about half an unit lower than 
in controls (F ig. 5) . The a f f i n i t y for the low a f f i n i t y binding si te and the 
proportions of high and low a f f i n i t y binding sites were normal. In tracheal 
smooth muscle tissue of patients with COB and emphysema unaltered isoprenaline 
binding properties were found (Fiq. 5 ) . 
fractional specific [ 1 2 5 l]-(-)-CYP binding 
1.0 
Ο θ 
06-
04-
02-
0 0 
рКн = 7 40 
pKL = 5 88 
'/.RH =33 
— ι 1 1 1 1 1 
-Θ -7 -6 -5 -4 -3 -2 
log isoprenaline (mol/I ) 
-12 -11 
-10 
Fig. 4: Fractional inhibition of [125ι]_(_)_ςγρ binding by isoprenaline to 
tracheal smooth muscle membranes of the patient with asthma. The curve 
was fitted to a two binding site model and the resulting isoprenaline 
binding parameters are given in the figure. 
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Fig. 5: Isoprenaline binding parameters in tracheal smooth muscle membranes. 
Binding characteristics were determined in [125I]-(-)-CYP 
competition experiments. All curves could be fitted adequately by a 
model of two classes of binding sites, RH and RL with 
corresponding affinity constants expressed as рКц and PKL. The 
relative proportion of high affinity sites is given as percentage of 
specific binding (%RH). Individual values are given (the figures 
refer to Table 1 "Autopsy") and horizontal bars indicate mean values. 
The mean + SE is given at the bottom of each column. Binding 
characteristics in patients with chronic obstructive bronchitis (COB) 
and emphysema were not significantly different from control values. 
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2. β-Adrenoceptor characteristics in lobar and segmental bronchial tissue 
A. [125i]-(.)-CYP binding 
Concentration-dependent [ 1 2 5 I ] - ( _ ) _ C Y P binding experiments were performed to 
investigate a l terat ions in ß-adrenoceptors in bronchial t issue of patients 
with COB (Table 1 , group B). Binding properties in patients and control 
subjects were similar (Table 2 ) . 
From 2 control subjects and 2 patients with COB lobar bronchial t issue was 
studied. These preparations had comparable ß-adrenoceptor densit ies and 
a f f i n i t i e s for [ l 2 5 l ] - ( - ) -CYP. To account for possible hyperplasia or 
hypertrophy of submucosal glands and smooth muscle c e l l s , the re la t i ve amounts 
of these tissue types were determined morphometrically in t issue sections of 
the bronchial samples. The areas of submucosal glands and smooth muscle t issue 
in patients with COB and control subjects appeared to be of comparable 
magnitude: (13.0 ± 1.6)« and (7.2 ± 1.7)% versus (13.2 ± 2.1)% and (8.8 ± 
1.3)% respectively (mean + SEM). 
Table 2: [125ι]_(_)_£γρ binding parameters in lobar and segmental 
bronchial t issue of control subjects and patients with chronic 
obstructive bronchit is (COB). 
pKd Rj (fmol/g) Ry (fmol/mg prot . ) 
Controls 11.34 ± 0.05 372 ± 6 9 45 ± 5 
(n » 9) 
COB 11.22 ± 0.05 376 ±64 39 ± 5 
(n = 8) 
Binding parameters of patients with COB and control subjects did not 
d i f f e r s i g n i f i c a n t l y . Values are the mean ± SEM. 
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В. Isoprenaline-induced relaxation 
The relaxation studies demonstrated differences between patients with COB 
(Table 1, Group C) and control subjects. Half of the pat ient 's group had lower 
pD2-values (F ig. 6) . The difference in mean pDj-values, however, did not 
reach s t a t i s t i c a l s ignif icance. We looked for a relat ionschip between 
p02-value and the degree of bronchial obstruction ( i . e . FEVj as percentage 
of predicted value) and the r e v e r s i b i l i t y of obstruction ( i . e . increase in 
FEVi after inhalation of salbutamol) but no s igni f icant correlat ion was 
found (r-values of 0.32 and -0.19 respect ively). 
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Fig. 6: 
Isoprenaline-induced relaxation of 
segmental bronchial st r ips without 
precontraction by methachol ine. 
Individual pDg-values and H i l l 
coef f ic ients (пц) are given (the 
f igures refer to Table 1, Group C) and 
horizontal bars indicate mean values. 
The mean ± SEM is given at the bottom 
of each column. Ttie mean pDj- and 
пн-values of patients with chronic 
obstructive bronchit is (COB) were not 
s i g n i f i c a n t l y d i f f e r e n t from control 
values. 
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С. Functional antagonism 
To investigate the balance between the muscarinic and ß-adrenergic receptor 
systems, we studied the sens i t i v i t y of segmental bronchial s t r ips to 
isoprenaline at d i f fe rent degrees of methacholine-induced tone. 
Contracting smooth muscle s t r ips of control subjects and patients with COB 
(Table 1, Group С patients 2,3,4,5,7,8 and 9) with 10-6 or IO"4 mol/1 
methachol ine resulted in a s h i f t of the isoprenaline dose-relaxation curves to 
the r i g h t (Fig. 7 A and Β), but relaxation curves in the presence of 10-6 
and Ю - 4 mol/1 methachol ine were next to s imi lar. The relaxation curves of 
the patients appeared to s h i f t to higher concentrations than those of control 
subjects. The mean isoprenaline pD2-value of maximally contracted smooth 
muscle st r ips of patients with COB was s i g n i f i c a n t l y lower than that of 
control subjects (P < 0.05). In both groups maximal contraction induced by 
methacholine could be reversed completely by isoprenaline. 
Legend to Figure 7; page 108 
Isoprenaline dose-relaxation curves of segmental bronchial s t r ips of control 
subjects (A) and patients with chronic obstructive bronchit is (COB) (B). The 
curves were recorded in the absence and presence of 10-6
 a n ( j io-4 mol/l 
methacholine (mech). ( i . e . relaxation from an " i n t r i n s i c tone", "halfmaximal" 
and "maximal precontraction" respect ively). The COB group comprised the 
patients 2,3,4,5,7,8 and 9 of group С in Table I. The maximal relaxation 
responses to isoprenaline in the presence of Ю - 4 mol/1 methacholine were 
similar in s t r i p s of control subjects and patients with COB: (120 ± 69)% and 
(107 ± 52)% respect ively, expressed as percentage of maximal contraction 
response (mean ± SEM). 
* S ign i f icant ly d i f f e r e n t from the pD2-value determined in the absence of 
methacholine (P < 0.05, Student's t - t e s t ) . 
+ 0.05 < Ρ < 0.10. 
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Figure 7A 
Figure 7B 
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DISCUSSION 
The objective of the present study was to investigate a possible 
ß-adrenoceptor dysfunction in airway smooth muscle of patients with 
obstructive lung disease, β-Adrenoceptor character ist ics were determined in 
tracheal smooth muscle and bronchial t issue in binding studies and relaxation 
experiments . 
[ 1 2 5 I ] _ ( _ ) _ C Y P binding experiments revealed that ß-adrenoceptors are 
present in normal density and have normal antagonist a f f i n i t y . Tlius, a 
deviating ß-adrenoceptor number is not a feature of obstructive lung disease. 
Tracheal smooth muscle tissue of patients with emphysema displayed normal 
isoprenaline sens i t i v i t y in relaxation experiments and demonstrated normal 
isoprenaline binding character is t ics. Although a l imited number of patients 
was studied, these resul ts make an impaired ß-adrenoceptor as a contr ibutory 
mechanism to emphysema unl ike ly . 
Airway smooth muscle t issue of patients with COB showed a large v a r i a b i l i t y 
in isoprenaline sens i t i v i t y and several patients had pD2-values considerably 
lower than control subjects. Ttie binding experiments, however, revealed normal 
isoprenaline binding character ist ics in tracheal smooth muscle membranes, 
making an impaired ß-adrenoceptor or defective coupling to adenylate cyclase 
unl ike ly . The reduced isoprenaline sens i t i v i t y might be caused by a higher 
i n t r i ns i c tone. This however seems less l i k e l y as the maximal relaxation 
response was comparable to that found in control subjects. A l ternat ive ly , i t 
might resul t from a less ef fect ive coupling between components of the relaxant 
system d is ta l to the ß-adrenoceptor. 
Most patients with COB were treated with theophyl l ine, salbutamol and 
prednisolone to improve lung funct ion. I t is well established that exposure to 
ß-adrenergic agonists and glucocorticoids may induce ß-adrenoceptor changes 
(15). The reduced isoprenaline sens i t i v i t y may therefore be a consequence of 
previous therapy. 
Our relaxation data are d i f f i c u l t to reconcile with those of Taylor et a l . 
(16) and Cerrina et a l . (8) who observed normal relaxation character ist ics in 
bronchial st r ips of patients with obstructive lung disease including COB. 
The discrepancy may be related to the d i f ferent recording condit ions, e.g. the 
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isotonic relaxations in our study and the isometric recording under a load of 
2-5 g used by them. 
Tracheal smooth muscle s t r i p s of the asthmatic patient in our study showed a 
markedly reduced isoprenaline s e n s i t i v i t y . Similar observations were made by 
others in bronchial s t r i p s of patients with asthma (7,8). Svedmyr and 
colleagues (17), however, reported normal dose-response curves for 
isoprenaline in bronchial s t r i p s of asthmatic pat ients. Thus, a reduced 
isoprenaline s e n s i t i v i t y in asthmatic airway smooth muscle remains a matter of 
controversy. To address the p o s s i b i l i t y that the reduced β-adrenoceptor 
function is caused by altered agonist binding propert ies, we measured 
i n h i b i t i o n of [ l 2 5 l ] - ( - ) - C Y P binding by isoprenaline. The a f f i n i t y of 
isoprenaline for the high a f f i n i t y s i te which is supposed to be pr imari ly 
involved in the act ivat ion of adenylate cyclase (18) was markedly reduced. 
This does not necessarily mean that the ß-adrenoceptor i t s e l f is impaired. The 
high a f f i n i t y state of the ß-adrenoceptor most probably is a ternary complex 
of agonist, ß-adrenoceptor and a stimulatory guanine nucleotide binding 
protein (18). Theoret ical ly, i t is thus possible that the reduced sens i t i v i t y 
for isoprenaline is due to an impaired stimulatory guanine nucleotide binding 
protein in one way or another. 
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SmMARY 
Bronchial hyperreact iv i ty, an enhanced sens i t i v i t y of the airways to i r r i t a n t 
s t imu l i , is a main character is t ic of asthma and is also frequently encountered 
in chronic obstructive bronchi t is . Hyperreactivity is supposed to be a 
consequence of a disturbed balance between the cont ract i le and relaxant 
mechanisms determining airway smooth muscle tone. The parasympathetic 
cholinergic system as well as the ß-adrenergic system s ign i f i can t l y contr ibute 
to the regulation of airway smooth muscle tone. Acetylcholine causes 
contraction by act ivat ing muscarinic receptors and adrenaline gives relaxat ion 
by stimulating ß-adrenergic receptors. 
In the present thes is , the question is addressed whether the disturbed 
balance is ref lected in measurable changes in the muscarinic and ß-adrenergic 
receptor systems involved. Muscarinic and ß-adrenergic receptors were 
investigated in tracheal musculature and bronchial t issue by radioligand 
receptor binding studies with membrane preparations and by contraction and 
relaxat ion experiments with smooth muscle s t r i ps . 
Chapter 1 is a b r ie f review on the cholinergic and adrenergic regulat ion of 
hunan airways in health and in obstructive lung disease and also describes 
some pharmacological and biochemical aspects of ß-adrenergic and muscarinic 
receptors. 
In chapter 2 and 3 the characterization of the muscarinic and the 
ß-adrenergic receptor population in tracheal smooth muscle of subjects free of 
airway disease is described. The muscarinic receptors were c lass i f ied as M 2 
receptors on basis of the re l a t i ve l y low binding a f f i n i t y of the M 1 select ive 
antagonist pirenzepine. The apparent a f f i n i t y of the muscarinic agonist 
methachoiine for inducing tracheal smooth muscle contraction was considerably 
higher than the a f f i n i t y for binding to the high and low a f f i n i t y agonist 
binding s i tes . This discrepancy indicates the presence of a substantial 
receptor reserve in the muscarinic receptor system in human tracheal smooth 
muscle. 
The ß-adrenergic receptors in tracheal smooth muscle are present in a very 
low concentration hampering an extensive character izat ion. Radioligand 
competition studies with selective ßi-antagonists revealed homogeneous 
ß2-adrenergic receptor populations in tracheal smooth muscle preparations 
113 
Summary 
of a l l subjects studied except one in which a small ßi-adrenergic receptor 
subpopulation was found. These findings are in accordance with relaxat ion 
character ist ics described in the l i t e ra tu re indicating a homogeneous 
ß2-adrenergic receptor population in human airway smooth muscle. Tlie 
presence of a small amount of ßi-adrenergic receptors in one patient most 
probably re f lec ts the minimal contr ibut ion of adrenergic nerves to airway 
smooth muscle re laxat ion. The a f f i n i t y of the ß-adrenergic agonist 
isoprenaline for the high a f f i n i t y state of the ß-adrenergic receptor was 
higher than i t s apparent a f f i n i t y for relaxing tracheal smooth muscle s t r ips 
having in t r ins ic tone. Assuming that the high a f f i n i t y state is responsible 
for the act ivat ion of adenylate cyclase, the discrepancy may be considered to 
be a consequence of poor coupling between the ß-adrenergic receptor and the 
relaxant response. 
Muscarinic receptors were also measured in bronchial tissue homogenates. 
These preparations are of heterogeneous composition and contain besides smooth 
muscle ce l ls other tissue types. In order to evaluate the or ig in of muscarinic 
receptors in the human bronchial t issue homogenates, the d is t r ibu t ion of 
muscarinic receptors was investigated autoradiographically ( chapter 4 ). As 
expected muscarinic receptors were localized in smooth muscle ce l l s and 
submucosal glands. They appeared to be present also in parasympathetic ganglia 
and peribronchial nerve bundles. The ro le of muscarinic receptors in these 
t issue types is unclear. 
Usually, bronchial t issue was obtained in quanti t ies insuf f ic ien t to measure 
muscarinic and ß-adrenergic receptors in separate assays. Therefore, a double 
receptor assay for simultaneous measurements was developed ( chapter 5 ). 
This double receptor assay is based on the d i f ferenta l counting of the 
t r i t i um and iodine-125 labels present in the muscarinic radioligand 
[3H]-(-)-Quinucl id inyl benzilate and the ß-adrenergic radioligand 
[125i]-(-)-Cyanopindolol respectively. Iodine-125 count rate can be measured 
d i r ec t l y in a γ-counter, t r i t i u n count rate is calculated i n d i r e c t l y after 
counting in a l i q u i d s c i n t i l l a t i o n counter. 
In chapter 6 the hypothesis of an increased muscarinic receptor s e n s i t i v i t y 
in tracheal smooth muscle and bronchial t issue of patients with asthma, 
chronic obstructive bronchit is and emphysema is addressed. 
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Neither receptor binding studies nor contraction experiments provided evidence 
in favour of the hypothesis. Muscarinic receptors in tracheal smooth muscle 
preparations are present in normal density and show normal antagonist binding 
a f f i n i t y and agonist binding character is t ics. The contraction studies also 
revealed normal receptor sens i t i v i t y . In segmental bronchial t issue of 
patients with chronic obstructive bronchit is also normal receptor numbers and 
contraction data were found. Morphometric examination of the l a t t e r 
preparations revealed normal mounts of smooth muscle ce l l s and submucosal 
glands. The excessive mucus production in chronic obstructive bronchi t is seems 
therefore not to be accompanied with an increased muscarinic receptor density 
in submucosal glands. 
In the f ina l chapter ( chapter 7 ) the ß-adrenergic receptor function in 
central airway smooth muscle of patients with asthma, chronic obstructive 
bronchit is and emphysema is studied. ß-Adrenergic receptors appeared to be 
present in normal density and to have unaltered antagonist binding a f f i n i t y . 
Thus, a diminished ß-adrenergic receptor number is not a character ist ic of 
obstructive lung disease. Tracheal smooth muscle tissue of patients with 
emphysema showed a normal isoprenaline sens i t i v i t y in relaxation and binding 
experiments, indicat ing that the ß-adrenergic receptor is not impaired in 
emphysema. Airway smooth muscle of patients with chronic obstructive 
bronchit is showed a reduced isoprenaline sens i t i v i t y in relaxation 
experiments. Since isoprenaline binding character ist ics were normal, the 
diminished sens i t i v i t y is l i ke l y a consequence of less ef fect ive coupling 
between the components of the relaxant system d is ta l to the ß-adrenergic 
receptor. However, i t remains to be established whether the reduced 
sens i t i v i t y to isoprenaline is not caused by previous exposure to 
bronchodilating drugs. Tracheal smooth muscle str ips of the patient with 
asthma also showed a reduced isoprenaline sens i t i v i t y in relaxation 
experiments. Concomitantly, the a f f i n i t y of isoprenaline for the high a f f i n i t y 
state of the ß-adrenergic receptor, which is supposed to be pr imar i ly involved 
in the act ivat ion of adenylate cyclase appeared to be markedly reduced. 
This anomalous binding behaviour could resul t from a defective ß-adrenergic 
receptor but i t could equally well be due to an impaired stimulatory guanine 
nucleotide binding prote in. 
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The resul ts presented in th is thesis indicate that follow-up studies on the 
autonomic control of airway smooth muscle in bronchial hyperreactivi ty should 
be aimed at exploring defects in the biochemical and electrophysiological 
mechanisms activated by ß-adrenergic receptor st imulat ion. 
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Bronchiale hyper reac t iv i te i t , een verhoogde gevoeligheid van de luchtwegen 
voor i r r i terende pr ikke ls , is een kenmerkende eigenschap van astma en is ook 
frequent aanwezig in chronisch obstructieve bronchi t is . 
De hyperreact iv i te i t wordt verondersteld een gevolg te z i j n van een verstoring 
in de balans tussen de contraherende en relaxerende mechanismen die de tonus 
van de luchtwegmusculatuur bepalen. Zowel het parasympathische cholinerge als 
het ß-adrenerge systeem spelen een belangrijke rol in de regulat ie van de 
spiertonus in de luchtwegen. Acetylcholine doet de spier contraheren door 
act ivat ie van muscarine receptoren en adrenaline geeft relaxat ie door 
st imulat ie van ß-adrenerge receptoren. 
In deze d isser tat ie wordt de vraag aan de orde gesteld of de verstoorde 
balans gepaard gaat met (meetbare) wijzigingen in de kenmerken van het 
muscarine en het ß-adrenerge receptor systeem in de luchtwegmusculatuur. 
Door middel van radioligand bindingsstudies aan membraan suspensies en 
contractie en relaxat ie experimenten aan glad spierweefsel preparaten, werden 
muscarine en ß-adrenerge receptoren in trachea spierweefsel en bronchi aal 
weefsel onderzocht. 
Hoofdstuk 1 bevat een kort overzicht van de cholinerge en adrenerge 
regulat ie van de humane luchtwegen en bespreekt een aantal farmacologische en 
biochemische aspecten van ß-adrenerge en muscarine receptoren. 
In hoofdstuk 2 en 3 worden de kenmerken van de muscarine en ß-adrenerge 
receptor populatie in spierweefsel u i t de trachea van individuen die niet 
leden aan ziekten van de luchtwegen beschreven. Op basis van de r e l a t i e f lage 
b ind ingsa f f in i te i t van de Ml selectieve antagonist pirenzepine werden de 
muscarine receptoren geclassif iceerd als M2 receptoren. De schijnbare 
a f f i n i t e i t waarmee methacholine, een agonist van het muscarine type, 
contract ie van de trachea spier induceert, bleek aanzienli jk hoger te z i j n dan 
de a f f i n i t e i t voor binding aan de hoge en lage a f f i n i t e i t s agonist 
bindingsplaatsen. De discrepantie w i j s t op de aanwezigheid van een 
aanzienli jke receptor reserve in het muscarine receptor systeem in de trachea 
spier van de mens. 
De ß-adrenerge receptoren komen in u i te rs t lage concentraties voor in de 
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trachea spier van de mens en deze omstandigheid bemoeil i jkte een uitgebreide 
karakter iser ing. Door middel van radioligand competitie experimenten met 
selectieve ßi-adrenerge antagonisten werd een homogene ß2-adrenerge 
receptor popul at ie aangetoond in al le trachea spierpreparaten van de onderzochte 
individuen met uitzondering van één waarin naast ßj-adrenerge receptoren een 
kleine ßj-adrenerge receptor populatie werd aangetroffen. Deze resultaten 
z i j n in overeenstemming met in de l i te ra tuur beschreven relaxat ie experimenten 
welke duiden op een homogene ß2-adrenerge receptor populatie in de humane 
luchtweg musculatuur. Het geringe aantal ßi-adrenerge receptoren in het 
betreffende individu weerspiegelt waarschi jn l i jk de minimale bijdrage van 
adrenerge zenuwen aan de re laxat ie van de luchtweg musculatuur. 
De a f f i n i t e i t van de ß-adrenerge agonist isoprenaline voor de hoge 
af f in i te i ts toestand van de ß-adrenerge receptor bleek hoger te z i j n dan de 
schijnbare a f f i n i t e i t waarmee in de tracheaspier, vanuit een int r ins ieke 
tonus, een relaxat ie kon worden geïnduceerd. Aannemende dat de activering van 
het adenylaat cyclase to t stand wordt gebracht via de hoge af f in i te i ts toestand 
van de receptor, kan verondersteld worden dat de koppeling tussen de 
ß-adrenerge receptor en het relaxerend systeem ine f f i c iën t i s . 
Muscarine receptoren werden eveneens gemeten in homogenaten van bronchi aal 
weefsel. Deze preparaten z i j n samengesteld van structuur en bevatten naast 
spiercellen andere weefseltypen. Teneinde vast te stel len in welke weefsel-
bestanddelen van het homogenaat de muscarine receptoren aanwezig waren, werd 
de locat ie in bronchiaal weefsel autoradiografisch bestudeerd (hoofdstuk 4 ) . 
Als verwacht werden muscarine receptoren in spierweefsel en submucosale 
kl ieren aangetroffen. Ze bleken bovendien in parasympathische ganglia en 
peribronchiale zenuwbundels aanwezig te z i j n . Welke rol muscarine receptoren 
in de laatst genoemde weefseltypen vervullen is vooralsnog onduidel i jk . 
In het algemeen werd bronchiaal weefsel ontvangen in gelimiteerde 
hoeveelheden, vaak onvoldoende om muscarine én ß-adrenerge receptoren 
afzonderl i jk te meten. Derhalve werd een z.g. dubbel receptor 
bepalingsmethodiek ontwikkeld voor simultane metingen van beide receptoren in 
hetzelfde homogenaat (hoofdstuk 5 ) . 
Deze bepalingsmethodiek is gebaseerd op de t e l l i n g van het t r i t i u n en 
jod1um-l25 labe l , die aanwezig z i jn in respect ievel i jk het muscarine 
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radioligand [3H]-(-)-Quinucl id iny l benzilaat en het ß-adrenerge radioligand 
[125i]_(_)_Cyanopindolol. De telsnelheden van het jodium-125 kunnen di rect 
gemeten worden in een gammateller, de t r i t i um telsnelheden worden indirect 
berekend na t e l l i n g in een v loeistof s c i n t i l l a t i e t e l l e r . 
In hoofdstuk 6 is de hypothese van een toegenomen gevoeligheid van de 
muscarine receptor in luchtwegmuscul atuur van patiënten met astma, chronisch 
obstructieve bronchit is en emfyseem aan waarnemingen getoetst. Voor deze 
hypothese werd noch in receptor bindingsstudies noch in contract ie 
experimenten ondersteuning gevonden. De dichtheid van de muscarine receptor en 
de a f f i n i t e i t van de receptor voor het gebruikte radioligand bleken normaal te 
z i jn in het trachea spierweefsel van deze patiënten. Tevens werden 
onveranderde kenmerken van de agonist binding aangetoond en wezen de 
contractie studies op een ongewijzigde muscarine receptor gevoeligheid. 
Normale muscarine receptor dichtheden werden eveneens aangetroffen in weefsel 
u i t de segmentale bronchiën van patiënten met chronisch obstructieve 
bronchi t is . Dit weefsel vertoonde evenmin een veranderde contract ie le 
respons. Morfometrisch onderzoek aan deze preparaten bracht geen noemens-
waardige wijzigingen in de hoeveelheden spier- en kl ierweefsel aan het l i c h t . 
De excessieve sii jmproductie in chronisch obstructieve bronchit is l i j k t 
derhalve niet vergezeld te gaan met een toegenomen muscarine receptor 
dichtheid in submucosale k l ie ren . 
Op grond van deze resultaten is het onwaarschijnl i jk dat een muscarine 
receptor defect betrokken is b i j bronchiale hyper reac t iv i te i t . 
In het laatste hoofdstuk (hoofdstuk 7) wordt de ß-adrenerge receptor funct ie 
in luchtweg museulatuur van patiënten met astma , chronisch obstructieve 
bronchit is en emfyseem beschreven. ß-Adrenerge receptoren bleken in normale 
dichtheden aanwezig te z i j n en een ongewijzigde a f f i n i t e i t voor het gebruikte 
radioligand te bezi t ten. Een verminderde ß-adrenerge receptor dichtheid l i j k t 
derhalve geen kenmerk van obstructieve longziekten te z i j n . Spierweefsel u i t 
de trachea van patiënten met emfyseem vertoonde een normale isoprenaline 
gevoeligheid in re laxat ie en bindingsexperimenten. Dit duidt op een 
ongewijzigde ß-adrenerge receptor b i j emfyseem. Spierweefsel u i t de luchtwegen 
van patiënten met chronisch obstructieve bronchit is vertoonde in re laxat ie 
experimenten een verminderde gevoeligheid voor isoprenaline die echter n iet 
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teruggevonden werd in gewijzigde bindingskarakteristieken voor isoprenaline. 
Het l i j k t daarom waarschi jn l i jk dat aan de verminderde gevoeligheid voor 
isoprenaline een minder effect ieve koppeling tussen de componenten van het 
relaxerend systeem distaal van de ß-adrenerge receptor ten grondslag l i g t . De 
vraag of de verminderde gevoeligheid niet een gevolg is van de 
bronchodilatoire therapie b l i j f t vooralsnog onbeantwoord. 
De trachea spierpreparaten van de patient met astma vertoonde eveneens een 
verminderde gevoeligheid voor isoprenaline in re laxat ie experimenten. Dit 
bleek vergezeld te gaan van een verminderde a f f i n i t e i t van isoprenaline voor 
de hoge af f in i te i ts toestand van de ß-adrenerge receptor; de toestand die 
verondersteld wordt d i rec t betrokken te z i j n b i j de activering van het 
adenylaat cyclase. Het afwijkend bindingsgedrag zou kunnen wijzen op een 
defecte ß-adrenerge receptor maar zou evenzeer te wi j ten kunnen z i jn aan een 
slecht functionerend guanine nucleotide bindend e iw i t . 
De resultaten beschreven in d i t proefschr i f t geven aan dat voorgezet onderzoek 
naar de autonome regulat ie van de luchtwegmusculatuur in bronchiale 
hyperreact iv i te i t gericht zou moeten worden op het detecteren van defecten in 
de biochemische en electrofysiologische mechanismen welke in gang gezet worden 
door ß-adrenerge receptor s t imulat ie . 
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